Annual Reports

  • 10-K (Jun 7, 2010)
  • 10-K (Jun 8, 2009)
  • 10-K (Jul 3, 2008)
  • 10-K (Jun 13, 2008)
  • 10-K (May 30, 2007)
  • 10-K (Mar 15, 2007)

 
Quarterly Reports

 
8-K

 
Other

Matrixx Initiatives 10-K 2008
e10vk
Table of Contents

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
Form 10-K
(Mark One)
     
þ   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended March 31, 2008
or
     
o   FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 001-31404
Matrixx Initiatives, Inc.
(Exact Name of Registrant as Specified in Its Charter)
     
Delaware   87-0482806
(State or Other Jurisdiction   (I.R.S. Employer
of Incorporation or Organization)   Identification No.)
8515 E. Anderson Drive
Scottsdale, AZ 85255
602-385-8888

(Address of principal executive offices,
Registrant’s Telephone Number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
     
Title of Each Class   Name of Each Exchange on Which Registered
     
Common Stock, $.001 par value   Nasdaq Global Select Market
Securities registered pursuant to Section 12(g) of the Act: None
     Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o   No þ
     Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o   No þ
     Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ   No o
     Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K, is not to be contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. þ
     Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
             
Large accelerated filer o   Accelerated filer þ   Non-accelerated filer o   Smaller reporting company o
        (Do not check if a smaller reporting company)    
     Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o   No þ
     The aggregate market value of the voting stock held by non-affiliates of the registrant was approximately $142.6 million based on the closing price of $19.78 per share of common stock as reported on the Nasdaq Global Select Market on September 28, 2007. For purposes of this determination, shares of common stock held by each officer and director and by each person who owns 5% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
     As of June 10, 9,629,962 shares of the registrant’s common stock were outstanding.
 
 

 


Table of Contents

DOCUMENTS INCORPORATED BY REFERENCE
     Portions of the Registrant’s definitive proxy statement prepared in connection with the Registrant’s 2008 annual meeting of stockholders are incorporated by reference into Part III, Items 10, 11, 12, 13 and 14 of this Form 10-K.
     Unless otherwise indicated in this Form 10-K, “Matrixx,” “us,” “we,” “our,” “the Company” and similar terms refer to Matrixx Initiatives, Inc. and its subsidiaries. “Zicam” is a registered trademark of our subsidiary, Zicam, LLC, and the Matrixx name and logo are trademarks of the Company.

2


 

TABLE OF CONTENTS
         
    Page
       
    4  
    10  
    15  
    15  
    16  
    20  
Supplemental Item.
       
    20  
 
       
       
    21  
    23  
    24  
    39  
    40  
    40  
    40  
    43  
 
       
       
    43  
    43  
    43  
    44  
    44  
 
       
       
    45  
 
       
    72  
 EX-21
 EX-23.1
 EX-31.1
 EX-31.2
 EX-32.1
 EX-32.2

3


Table of Contents

PART I
ITEM 1. BUSINESS
Introduction
     We develop, produce, market and sell innovative, over-the-counter (OTC) healthcare products with an emphasis on those that utilize unique, novel and/or proprietary delivery systems that provide consumers with “Better Ways to Get Better®.” Through our subsidiaries, we produce, market and sell products under the Zicam®, Nasal Comfort™, and Xcid™ brands. As discussed in more detail below, our current Zicam and Nasal Comfort product offerings compete in the following four product classes within the cough and cold category: Cold Remedy; Allergy/Sinus; Cough; and Multi-Symptom Cold/Flu relief. Our Xcid brand antacid competes within the over-the-counter antacid category.
     We were incorporated in Utah in 1991 as Gum Tech International, Inc. On June 18, 2002, we reincorporated in Delaware and changed our name from Gum Tech International, Inc. to Matrixx Initiatives, Inc. We generally conduct our business through our wholly owned subsidiaries. We develop and market our Zicam, Xcid, and Nasal Comfort products through Zicam, LLC. We are developing our oral care product concepts through Zicare, LLC, which we formed in 2006. In May 2008, we formed Zicam Canada, Inc. to commercialize sales of Zicam products in Canada.
     We have sales in one business segment, over-the-counter pharmaceuticals. Currently, all of our revenues are attributed to sales within the United States; however, we anticipate entering international markets in the future and expect initial sales to occur in Canada in fiscal 2009. Our net sales were approximately $101.0 million for the fiscal year ended March 31, 2008, compared to net sales for the twelve months ended March 31, 2007 of approximately $97.6 million. Our net income was $10.4 million for the fiscal year ended March 31, 2008, and $6.5 million for the twelve months ended March 31, 2007.
     As used herein, except as otherwise indicated, references to “we,” “us,” “our,” or the “Company” refer to Matrixx Initiatives, Inc. and its subsidiaries.
Access to Our Filings with the Securities and Exchange Commission
     Our website is www.matrixxinc.com. Through a link on the Investor Relations section of our website, we make available the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the SEC: our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934. All such filings are available free of charge. Information contained on the Company’s website is not part of this report.
     Our principal executive offices are at 8515 E. Anderson Drive, Scottsdale, AZ 85255 and our telephone number is (602) 385-8888.
Markets and Company Products
     Our current Zicam products are marketed in the cough and cold market category. That market, which is estimated at more than $4.0 billion annually in retail sales in the United States, includes a wide variety of tablets, liquids, gels, sprays, and syrups that remedy and/or provide relief to cold, allergy and sinus congestion sufferers. The largest sub-segment of the cough and cold category includes products formulated to relieve symptoms associated with the common cold. It is estimated that more than one billion common colds occur in the United States each year, with over 100 million of these colds resulting in lost days of school or work, or some level of restricted activity. Colds are estimated to occur at a rate of two to five per person (six to eight per child) each year. The market for allergy relief products covers a much smaller segment of the population, estimated at 35 million people in the

4


Table of Contents

United States. However, allergy sufferers, compared to cold sufferers, are more likely to require medication for a much longer period of time to relieve allergy symptoms.
     In February 2007, the Company changed its fiscal year-end from December 31st to March 31st. The following table details our sales by product class for the periods indicated, with further details below:
                                                                 
    12 months ended             12 months ended             12 months ended             12 months ended        
Product Class   March 31, 2008     %     March 31, 2007     %     December 31, 2006     %     December 31, 2005     %  
Cold Remedy
  $ 68,225,508       68 %   $ 69,093,132       71 %   $ 69,046,345       72 %   $ 55,292,673       61 %
Allergy/Sinus/Nasal Comfort
    17,325,720       17 %     16,109,489       17 %     15,468,683       16 %     20,163,688       23 %
Cough
    4,461,208       4 %     6,143,165       6 %     6,059,285       6 %     6,514,769       7 %
Multi-Symptom Cold/Flu
    10,607,287       11 %     6,254,790       6 %     5,656,467       6 %     8,489,465       9 %
Antacid
    352,661       0 %     0       0 %     0       0 %     0       0 %
 
                                               
Total Net Sales
  $ 100,972,384       100 %   $ 97,600,575       100 %   $ 96,230,780       100 %   $ 90,460,595       100 %
 
     Cold Remedy
     Zicam Cold Remedy was formulated to reduce the duration and severity of the common cold. In a study published in the October 2000 issue of the ENT- Ear, Nose & Throat Journal, Zicam Cold Remedy was shown to reduce the duration of the common cold when taken at the onset of symptoms. In a separate study published in the January 2003 issue of QJM: An International Journal of Medicine, zinc gluconate nasal gel (Zicam Cold Remedy) was shown to reduce the duration and symptoms of the common cold when treatment was started as late as the second day of illness. We believe Zicam Cold Remedy is unique in the cough and cold market category due to the product’s ability to reduce the duration of the common cold. Customer awareness of the products has increased as a result of our marketing and public relations efforts and word-of-mouth experience by consumers.
     Our original product, Zicam Cold Remedy nasal pump, is a homeopathic nasal gel product based on our patented zinc gluconate delivery system and was introduced in 1999. We introduced Zicam Cold Remedy Swabs in late 2002 to appeal to consumers who dislike nasal sprays. In November 2005, we acquired substantially all of the assets of Viridian a manufacturer of dry handle swab products. The principal assets acquired included a patent related to dry handle swab technology and other associated intellectual property. Additional assets included equipment, machinery and tooling. The Company’s ownership of this intellectual property facilitated partnering with a contract manufacturer to build and operate a new automated manufacturing line to meet increased demand for the swab products. The Company invested approximately $4.2 million in a new manufacturing line to produce the Company’s improved swab product, which includes a recessed score in the swab container that users can snap to open. The new equipment began production and we began shipping the improved swab product during the fourth calendar quarter of 2006.
     In order to meet the needs of customers who dislike any form of nasal applications, we introduced three oral delivery forms of Zicam Cold Remedy products in late 2003 (Zicam Cold Remedy Chewables, Zicam Cold Remedy RapidMelts, and Zicam Cold Remedy Oral Mist). The oral Cold Remedy products are designed to rapidly deliver a dose of ionic zinc to the oral mucosa. We believe that this feature allows the consumer to avoid much or all of the stomach upset that has been associated with zinc lozenges on the market. During 2006, the Company introduced two additional oral delivery forms of Zicam Cold Remedy: Zicam Cold Remedy RapidMelts + Vitamin C and Zicam Cold Remedy ChewCaps.
     Allergy/Sinus
     Zicam Allergy Relief, a homeopathic nasal gel formula, was introduced in 2000. Zicam Allergy Relief is designed to control allergy symptoms for sufferers of hay fever and other upper respiratory allergies. We believe Zicam Allergy Relief is distinctive from most allergy products available on the market due to the absence of side effects such as drowsiness. We introduced two allopathic Zicam nasal gel products in late 2002: Extreme Congestion Relief and Sinus Relief. Zicam Extreme Congestion Relief is a nasal gel that combines the active ingredient oxymetazoline hydrochloride into our gel matrix and soothing aloe vera to provide fast-acting, long- lasting relief of nasal congestion and sinus pressure. Zicam Sinus Relief provides all of the benefits of the Extreme product with the aromatic strength of a cooling menthol/eucalyptus blend.

5


Table of Contents

     The Company began shipping Nasal Comfort, a new brand and product for nasal health, during the third quarter of 2005. Nasal Comfort is a unique product designed to help maintain the critical functions of the nasal cavity and its role in the respiratory process. The product is a preservative-free, sterile, hypertonic aqueous solution with essential salts and oils that cleanses and moisturizes the nose. This brand was initially targeted to the drug trade and has not achieved widespread distribution or consumer acceptance. Beginning in 2006, the Company has experienced a large amount of returns for this product. During fiscal 2008, the Company reduced the price for Nasal Comfort in an effort to increase consumer acceptance of the product..
     Cough
     In 2004, we introduced several Zicam Cough Spray products designed to deliver fast, effective cough relief and soothe throat irritation. We increased our cough product offerings in the third quarter of 2005 with the addition of Zicam Cough Mist Max, a more powerful liquid spray formulation that provides eight hours of relief. Several of the cough spray stock keeping units, or SKUs, did not realize the growth rates we anticipated, and as a result, during fiscal 2008, we consolidated the number of cough spray products to the Cough Max spray product. Our Zicam Cough Max spray product utilizes a unique spray delivery system that is convenient and portable, with no messy measuring or sticky syrups, to deliver the active ingredient most recommended by doctors to quiet a cough. Additionally, we introduced a Zicam Cough Melt product in the third calendar quarter of 2006, which utilizes quick dissolve technology and delivers eight hours of cough relief via a rapid dissolve tablet. The Company is currently marketing the Cough Max spray and the Cough Melts.
     Multi-Symptom Cold & Flu Relief
     In the third calendar quarter of 2005, we began shipping our line of Zicam Multi-Symptom Cold & Flu Relief products. The initial products utilized a spoon dosing delivery. Each spoon is individually packaged and dosed with medicine to provide powerful relief of cold and flu symptoms. The spoon delivery is designed to be mixed with any beverage, hot or cold. During fiscal 2008, we introduced two new multi-symptom products for the 2007/2008 cold season. The new products expanded upon our existing flavor-neutral product by providing consumers a liquid that can be poured into any beverage (hot or cold) for relief of cold and flu symptoms. The two new multi-symptom products replaced two of the original multi-symptom flu relief products previously available in the spoon dosage form and are being sold at a lower price per unit.
     Antacid
     Xcid, a smooth creamy antacid, was introduced in the fourth quarter of fiscal 2008, with one large national retailer. The antacid category generally consists of large well known brands that have products to either neutralize acid or block acid production. Xcid antacid competes with other acid neutralizing products. Introducing a new brand is challenging and it takes time to build awareness and trial. We anticipate sampling and marketing activities to begin in fiscal 2009 to build trial and awareness for the product.
     Product Pipeline
          We continue to believe there are opportunities to expand the Zicam brand within the cough and cold category. In the past we have introduced Zicam line extensions and new delivery forms, and we anticipate that to continue. We are also investigating product opportunities in other categories, including oral care and cold sore.

6


Table of Contents

     Business Strategy
     Our business objective is to be a growth oriented over-the-counter (OTC) healthcare company marketing products that utilize novel, unique and proprietary delivery systems that provide consumers with “Better Ways to Get Better®.” To achieve our objective, the key elements of our business strategy include the following:
     Expanding Marketing Efforts for Existing and New Products: We intend to continue to develop and refine our sales and marketing efforts to increase market penetration of our products in U.S. households. Such efforts include improving the timing and consistency of marketing activities, executing effective trial generating programs, implementing programs with retailers to enhance consumer awareness of our products, and seeking to increase recommendations from healthcare professionals. We are continuing to implement new creative advertising approaches and public relations efforts. We believe these efforts will continue to build brand awareness, trial, and sales of our products. Additionally, we anticipate introducing several Zicam products in the Canadian marketplace during the 2008/2009 cold season. We will engage a Canadian distributor to perform retail sales there.
     Pursuing Additional Delivery Systems and Expansion into New OTC Categories: Our success in expanding consumer acceptance of our Zicam products confirms our belief that opportunities exist to pursue development of other healthcare products that deliver consumer benefits utilizing unique, novel and/or proprietary delivery systems. We are seeking to identify, through internal research and development efforts and through consideration of external acquisition opportunities, other growth opportunities for Matrixx and are specifically targeting product concepts in the oral care, antacid, and cold sore markets as well as in the cough and cold market category in which we currently compete.
Customers
     We sell our products directly to major food, drug, mass market (e.g., Wal-Mart, Target) and wholesale warehouse retailers throughout the United States, and to distributors that sell to smaller retail establishments. Zicam Cold Remedy Nasal Pump, Zicam Cold Remedy Swabs, Zicam Cold Remedy Rapid Melts, Zicam Allergy Relief, and Zicam Extreme Congestion Relief are sold in virtually every major food, drug, and mass merchant retail outlet in the country. Our other Zicam and Nasal Comfort products have not achieved the same level of distribution. We are highly dependent on a small group of large national retailers for our product distribution, such that our top 15 customers accounted for more than 80% of our net sales in fiscal 2008, and three customers each accounted for more than 10% of our net sales in fiscal 2008 (Wal-Mart, 23%; Walgreens, 13%; and CVS, 12%). During the prior twelve months ended March 31, 2007, our top 15 customers accounted for approximately 80% of our net sales, and three customers accounted for more than 10% of the year’s net sales (Wal-Mart, 23%; Walgreens, 13%; CVS, 13%). Our agreements with our customers generally permit them to return unsold merchandise, limited to damaged, out-of-date, or discontinued products. We provide in our financial results, as an offset against sales, an estimate for expected returns (see Note 4 to the Consolidated Financial Statements). During fiscal 2008, we experienced a high amount of product returns related to several discontinued products. In fiscal 2008, we recorded an increase to our returns allowance of approximately $3.1 million, in excess of our customary reserve, to account for this increase in returns. To the extent that any of our largest customers were to stop carrying our products for any reason, or were to fail to pay us for our products, our sales and financial results could be negatively impacted in a material way.
     Prior to fiscal 2008, we contracted with a third party organization to provide sales management and broker oversight. During fiscal 2008, we hired and trained our dedicated sales force to call on national and regional retail accounts, wholesale distribution companies, and to oversee brokers. We rely on brokers to provide retail support to our more fragmented and smaller customers. Our new sales force is focused on increasing distribution, improving shelf placement of our products, and developing trade promotional programs.
Manufacturing and Distribution
     Our products are manufactured and packaged by third-party manufacturers. Each of our manufacturers is registered with the federal Food and Drug Administration (FDA) as a drug facility, which requires each manufacturer to adhere to current Good Manufacturing Practices in its production processes and procedures. Each manufacturer is responsible for sourcing raw materials used in its production of our products from third party suppliers. We rely on individual production orders to meet our needs from these suppliers. We are in the process of

7


Table of Contents

negotiating contracts with certain manufacturers at this time. We have some flexibility in securing other manufacturers to produce our products; however, in some circumstances we may be limited in our alternatives due to proprietary technologies that are utilized in some of the products.
     Our manufacturers are subject to reporting, facility inspection, and governmental review. In general, subsequent discovery of previously unrecognized problems or failure to comply with applicable regulatory requirements could result in restrictions on manufacturing or marketing of the products, product recalls or withdrawal, fines, seizure of product, as well as withdrawal or suspension of regulatory approvals. The manufacturer of several of our products is in the process of responding to observations made by the FDA during a routine facility inspection. We do not know how the conclusions of this review process might impact our products or business, but the review could result, with regard to those products manufactured at the facility, in any or all of the above consequences, including the possibility of a product recall.
     We generally source packaging materials, including bottles and sprayers, from third parties. We use third-party manufactures and packagers for production processes including compounding and producing product mixtures, filling bottles, assembling finished product and packing finished product in master cases. In several instances our drug manufacturers ship bulk formula to our packaging contractors to fill product into primary and secondary packaging and assemble finished product in master cases. Finished products are shipped to an independent warehouse in Indiana for storage prior to shipment to our customers. We recently consolidated to one warehouse to reduce costs.
Research and Development
     Research and development of new products is an important part of our business. Expenditures during fiscal 2008 reflect costs associated with the multi-symptom and antacid products introduced in fiscal 2008, as well as expenses associated with line extensions we anticipate introducing in fiscal 2009 and in future years. During 2008, research and development expenses were $4.1 million, or 4% of 2008 net sales. We expect to commit approximately 3% to 4% of net sales on research and development in subsequent years in order to develop a pipeline of new products to be introduced in the future to meet our sales growth targets. Research and development expense was approximately $4.7 million for the twelve months ended March 31, 2007, and $4.7 million and $4.1 million during the fiscal years ended December 31, 2006, and 2005, respectively.
FDA, FTC and Other Government Regulation
     We are subject to various federal, state and local laws and regulations that affect our business. All of our products are subject to regulation by the FDA, including regulations with respect to manufacturing processes and procedures, ingredients in the products, labeling and claims made. Our drug products are commercially distributed by following the Homeopathic Pharmacopeia or FDA’s OTC monographs. The OTC monographs classify certain drug ingredients as safe and effective for specified uses and establish categorical requirements for the marketing of drugs containing such ingredients without pre-approval. All of our Zicam Cold Remedy products and Zicam Allergy Relief are subject to the requirements of the Homeopathic Pharmacopeia of the United States. Zicam Extreme Congestion Relief, Zicam Sinus Relief, the Zicam cough products, and the Zicam multi-symptom relief products are subject to the requirements of the FDA as allopathic drugs. All of our claims and advertising are subject to the rules of the Federal Trade Commission (FTC). Although we believe that our products and claims comply in all material respects with the regulatory requirements, if the FDA or FTC were to determine that we are in violation of any such requirement, either agency could restrict our ability to market the products, require us to change the claims that we make or cause us to remove the products from the market.
     On March 5, 2007, the FTC’s East Central Region (Cleveland, Ohio office), notified the Company that it is no longer pursuing an inquiry into the Company’s advertising and promotional activities for several of the Company’s Zicam products, including, Zicam® Cold Remedy Nasal Gel and Zicam Cold Remedy Swabs. The inquiry was initiated pursuant to a letter from the FTC’s staff that management received on March 21, 2006, as supplemented by a letter dated October 16, 2006, to determine whether the Company engaged in unfair or deceptive acts or practices in violation of the Federal Trade Commission Act.
     On March 10, 2005, the National Advertising Division (NAD) of the Council of Better Business Bureaus, an investigative arm of the advertising industry’s voluntary self-regulation program, issued a press release announcing the results of a review of Matrixx’s advertising claims. The NAD determined, among other things, that Matrixx’s claims that its product, Zicam® Cold Remedy Nasal Gel, resolves colds three times faster when taken at the first

8


Table of Contents

sign of a cold, that using the product results in a less severe cold, and the promise that these benefits are clinically proven, were substantiated by competent and reliable scientific evidence.
Environmental Matters
     Compliance with environmental rules and regulations did not significantly affect our earnings or competitive position during fiscal 2008, the three months ended March 31, 2007, or during fiscal 2006. All of our Zicam product manufacturing and warehousing operations are currently outsourced to third party contractors and, as a result, we do not incur any direct expenses related to environmental monitoring and regulatory compliance. With our continued outsourcing of Zicam product manufacturing and storage, and no present plans to direct manufacture or store our products, we expect these expenses to remain low in the foreseeable future. To the extent higher costs are incurred by our manufacturers for environmental compliance, they could impact our cost of goods.
Trademarks, Trade Names, and Proprietary Rights
     We have been issued four United States patents (U.S. Patent Nos. 6,080,783, 6,365,624, 6,673,835 and 7,348,360) for the Zicam® Cold Remedy nasal technology and one patent for the Gel SwabTM technology (U.S. Patent No. 7,115,275). In October 2005, we acquired a patent (U.S. Patent No. 6,516,947) and other associated intellectual property related to the dry handle swab technology used in manufacturing the Zicam® Cold Remedy Gel Swab™ products. We believe these patents, which are expected to be effective until September 1, 2018 for the Cold Remedy nasal technology, August 11, 2020 for the dry handle swab technology, and September 16, 2023 for the Gel SwabTM technology afford significant protection from competitors that may wish to sell similar products. We also have additional patent applications on file in the United States to seek further rights in the Cold Remedy delivery technology. We have related issued patents in Australia (No. 774410), Canada (No. 2,308,513) Korea (No. 439,323), and China (No. 99801986.0) and have pending applications in several other countries and regions, including Mexico, the European Union, Hong Kong, Japan, Brazil and India. Patent applications are pending in the United States for compositions and methods relating to Zicam® Nasal Moisturizer™, Zicam® Extreme Congestion Relief, Zicam® Intense Sinus Relief, Zicam® Cold Remedy RapidMelts®, Zicam® Cold Remedy Chewables™, Zicam® Cold Remedy Oral Mist™, Zicam® Cold Remedy Gel Swabs™, Zicam® Multi-Symptom Cold & Flu, Zicam® Cough Max TM cough spray, Nasal Comfort®, and oral care technology. We have preserved our rights to file applications for several of these products in other foreign countries at a later date and have been issued a patent for Cold Remedy Oral Mist in the European Union. We hold registrations for the Zicam® trademark in the United States, the European Union, Japan, Australia, Canada, Mexico, Taiwan, and China and have applied for similar trademark protection in Brazil. We also hold additional registrations for the Better Ways to Get Better®, The Cold Solution®, RapidMelts®, No-Drip Liquid®, Cough Mist®, and Nasal Comfort® trademarks in the United States. We anticipate that we will continue to file for patent and trademark protection for the other products we expect to develop and introduce in the future. There can be no assurance, however, that our existing patents, or any additional patents that we may secure in the future, will be adequate to protect the Company’s intellectual property from a competitor’s actions or that the Company’s products will not be found to infringe the intellectual property rights of others. Further, patent infringement litigation can be very time consuming and costly. Even if we prevail in such litigation, the cost of litigation could adversely affect our operating results and financial condition.
Employees
     As of June 1, 2008, we had 36 employees. Currently 31 of our employees work in our Scottsdale, Arizona corporate office and five of our sales personnel work from home offices in other states. Our employees consist of executive officers and individuals responsible for administration, operations, marketing, sales, research and development, regulatory compliance, finance, and accounting.
Seasonality; Change of Fiscal Year
     Retail sales of Zicam products to end-user consumers are highly seasonal, with most sales generally occurring during the cold and flu, and to a lesser degree, the allergy seasons. The cold season generally runs from October

9


Table of Contents

through March, while the allergy season runs from April through October. Both of these seasons can vary in intensity and duration from year to year. Our sales to retailers generally mirror this pattern of consumer demand, but are impacted by the level of promotional support we commit to retailers and by their inventory management practices. During the third calendar quarter, the Company usually receives orders from retailers preparing for the cold season. The quarter ended September 30 has historically been the most profitable quarter during our fiscal year, as retailers increase inventory, and there is no increase in marketing expense. Generally, the quarter ended June 30 accounts for 7% to 8% of annual sales, and the Company has historically recorded negative earnings in that quarter.
     Because of the extreme seasonality in the Company’s business, on February 9, 2007, the Company’s Board of Directors approved a change in the Company’s fiscal year end from December 31 to March 31 in order to better align the Company’s operations and financial results with the entire cold season. The three months ended March 31, 2007, was the Company’s transition period, and the Company’s new fiscal year began April 1, 2007 and ended March 31, 2008.
Backlog
     There were no significant product backlogs at March 31, 2008 or 2007, or at December 31, 2006 or 2005.
Competition
     All of the Zicam and Nasal Comfort products compete in the highly competitive over-the-counter cold, allergy/sinus, cough, and flu market groups of the overall cough and cold category with a vast number of well-established brands marketed by large pharmaceutical and consumer products companies. Participants in the cough and cold category compete primarily on the basis of price, quality of product, and brand recognition. Most of our competitors have substantially greater financial, marketing and other resources, longer operating histories, larger product portfolios and greater brand recognition than we do. With our limited resources, we are aiming to succeed in this category by emphasizing the unique claims regarding our products and providing consumers with innovative delivery systems. Specifically, regarding Zicam Cold Remedy, our flagship product, we emphasize its ability to reduce the duration and severity of the common cold, while the majority of products in the cough and cold category just make claims associated with the relief of symptoms.
     Xcid antacid competes in the over-the-counter antacid category. The antacid category generally consists of two types of products, acid neutralizers and acid inhibitors. Xcid competes with other branded and private label acid neutralizers in tablet and liquid form. Acid inhibitors are generally prescription-to- OTC switch products. Most of the competitors in this category have substantially greater financial, marketing and other resources, longer operating histories, larger product portfolios and greater brand recognition than we do. We are aiming to compete on taste and delivery by emphasizing the unique creamy texture of our product as well as its taste.
     We utilize data from independent market research firms, including Information Resources, Inc. (“IRI”), to assess market share, size, and ranking of our products and brands versus competitors. IRI reports retail sales in food, drug, and mass merchant markets, and does not include our largest customer, Wal-Mart. Zicam products have gained market share every cold season since introduction and, for the 52 weeks ended March 23, 2008, Zicam achieved a 2.9% dollar share of the $4.2 billion cough/cold category as measured by IRI, which is a 0.1% share increase from the prior year.
ITEM 1A. RISK FACTORS
We may fail to compete effectively, particularly against larger more established pharmaceutical and health products companies, or low cost generic drug manufacturers, causing our business and operating results to suffer.
     The consumer health products industry is highly competitive. We compete with companies that are engaged in the development of both traditional and innovative healthcare products. Many of these companies have much greater financial and technical resources, and production and marketing capabilities than we do. As well, many of these companies have already achieved significant product acceptance and brand recognition with respect to products that compete directly with our products. We also compete with private label manufacturers that may try to develop and

10


Table of Contents

market products similar to ours. Our competitors may successfully develop and market superior or less expensive products which could render our current and future products less valuable or unmarketable.
Our business is subject to seasonality that may cause our quarterly operating results to fluctuate materially and cause the market price of our stock to decline.
     Sales of our existing Zicam products are extremely seasonal in nature and are dependent upon the severity of the cough and cold season. Sales at retail generally increase as the level of population suffering from colds rises. During the quarter ending September 30, the Company usually realizes increased sales volume as retailers stock our products and order displays to prepare for the upcoming cough and cold season. Additional sales (re-orders) to retailers are highly dependent upon the incidence of illness within the population. Retail consumption of our products is highest during the cough and cold season, which usually runs from October through March. If there is a mild cold/flu season, revenues from sales of our Zicam products will be adversely affected. Because it is difficult to anticipate the length and severity of the cold/flu season, we cannot estimate the fluctuation of our sales from quarter to quarter in a fiscal year or the impact of the cold/flu season year to year. If our operating results fall below financial analysts’ or investors’ expectations due to cold/flu seasonality factors, the market price of our common stock may decline.
     Because of the extreme seasonality of the Company’s business, on February 9, 2007, the Company’s Board of Directors approved a change in the Company’s fiscal year end from December 31 to March 31 in order to better align the Company’s operations and financial results with the entire cold season. The three months ended March 31, 2007 was the Company’s transition period and the Company’s new fiscal year began April 1, 2007 and ended March 31, 2008.
We may continue to incur significant costs resulting from product liability claims or securities litigation.
     Numerous lawsuits have been filed against us alleging that our Zicam Cold Remedy nasal gel product caused the permanent loss or diminishment of the sense of smell and taste. Various defendants in the lawsuits, including manufacturers and retailers, have sought indemnification or other recovery from us for damages related to the lawsuits. Although we carry product liability insurance, there is no assurance that our insurance will be adequate to cover liability in connection with these product liability lawsuits, or that product liability insurance will continue to be available to us at an economically reasonable cost. Although we believe the product liability claims are without merit, they have resulted in significant legal defense and settlement costs, which have increased our expenses and lowered our earnings. Such claims, whether or not proven to be valid, could have a material adverse affect on our brand equity and goodwill, resulting in reduced market acceptance of our products. In addition, any adverse decision in such litigation could require significant damages to be paid or result in adverse publicity, either of which could materially adversely affect our results of operations and financial condition. Separately, the Company and three of its officers are also subject to two class action lawsuits (which have been consolidated) alleging violations of securities laws. Any adverse decision in such litigation could materially adversely affect our results of operations and financial condition.
Because a significant portion of our business depends substantially on a small group of large national retailers, our sales, operating margins and income would be adversely affected by any disruption of our relationship with these retailers, or any other material adverse change in such retailers’ businesses.
     We are highly dependent on a small group of large national retailers for our product distribution, such that our top 15 customers accounted for more than 80% of our net sales in fiscal 2008 and prior years. Three customers, Wal-Mart, Walgreens, and CVS, together accounted for 48% of sales in fiscal 2008, 49% of our net sales in the twelve months ended March 31, 2007, and approximately 50% of net sales in fiscal 2006. Should any of our top customers encounter financial difficulties, stop carrying our products for any reason, or should our current relationship with any of our top customers adversely change in any way, the resulting loss of business, exposure on uncollectible receivables and unusable inventory could have a material adverse impact on our financial position and results of operations. In addition, our results could be affected by fluctuations in buying patterns and inventory levels of these top customers.

11


Table of Contents

Our entry into international operations exposes us to numerous risks.
     We anticipate introducing several Zicam products in the Canadian marketplace during the 2008/2009 cold season and, although we do not expect to have a physical presence in Canada, we will be subject to risks inherent to doing business internationally. These risks may affect our future operations and include: regulatory approvals; developing consumer acceptance in a foreign market; economic downturns; foreign currency exchange rate fluctuations; international incidents; tax laws; transportation delays; protecting our intellectual property; and changes in regulatory requirements. Any of these factors could have a material adverse affect upon our operations and financial results.
We believe that growth in the over-the-counter healthcare products market is driven, in part, by factors beyond our control, such as media attention, adverse publicity, and regulatory changes. If the factors currently having a positive impact on this market disappear or diminish, our sales in this market may suffer.
     In the event of future unfavorable scientific results or media attention, sales of our products could be materially adversely affected. In addition, if issues arise concerning the efficacy or safety of any of our products, or if any of our products receive additional adverse publicity, our operating results and prospects could be materially adversely affected. Changes in the regulatory environment that restrict certain over-the-counter active drug ingredients could have materially adverse affects on sales of our products.
Our future growth will depend in part upon our ability to develop and achieve sales of new products.
     Although we believe that each of our products offers unique benefits to consumers, we cannot be certain that any of the products will achieve or continue to enjoy widespread acceptance by the market. While we are working to increase the market presence of all of our products, including new products, we cannot be certain that demand for our products will grow. Building a new brand presence may take time and require large marketing expenditures. If new products or brands do not achieve consumer acceptance, operating results could be materially adversely affected.
Unanticipated problems associated with product development and commercialization could adversely affect our operating results.
          Our successful maintenance of existing and development of new products are subject to the risks of failure and delay inherent in the development and commercialization of products based on innovative technologies. These risks include the possibilities that:
    we may experience unanticipated or otherwise negative research and development results;
 
    existing or proposed products may be found to be ineffective or unsafe, or may otherwise fail to receive required regulatory clearances or approvals;
 
    we may find that existing or proposed products, while effective, are uneconomical to commercialize or market;
 
    we may be unable to produce sufficient product inventories to meet customer demand;
 
    we may experience adverse publicity from product liability lawsuits that could materially impact consumer demand;
 
    existing or proposed products do not achieve broad market acceptance;
 
    existing or proposed products do not attain broad distribution or retail shelf space; or
 
    proprietary rights held by third parties may preclude us from developing or marketing existing or proposed products.

12


Table of Contents

          Research, development and testing can be long, expensive and uncertain processes. Our future success depends, in part, on our ability to complete development of products. If we are unsuccessful in advancing our early stage products into marketable consumer-ready products for any reason, our business prospects could be harmed.
The inability to provide scientific proof for product claims may adversely affect our sales.
          The marketing of our Zicam products involves claims that these products assist in reducing the duration and severity of the common cold (in the case of Zicam Cold Remedy products) and controlling allergy symptoms (in the case of Zicam Allergy Relief). Under FDA and FTC rules, we are required to obtain scientific data to support any claims we make concerning our products. We have scientific data for our product claims; however, we cannot be certain that these scientific data will be deemed acceptable to the FDA, FTC or other regulatory bodies. If any regulatory body requests supporting information and we are unable to provide support that is acceptable, either the FDA or FTC could force us to stop making the claims in question or restrict us from selling the affected products.
FDA and other government regulation may restrict our ability to sell our products or require us to recall products.
          We are subject to various federal, state and local laws and regulations affecting our business. Our Zicam products are subject to regulation by the FDA, including regulations with respect to manufacture and labeling of products, approval of ingredients in products, claims made regarding the products, and disclosure of product ingredients. If we, or our third-party manufacturers, do not comply with these regulations or if these regulations change in the future, the FDA could force us to stop selling the affected products or require us to incur substantial costs in adopting measures to maintain compliance with these regulations. If the FDA came to believe that any of our products do not comply with the regulations or caused harm to consumers, we could be required to stop selling that product or subject the product to a recall. Our advertising claims regarding our products are also subject to the jurisdiction of the FTC. In both cases we are required to posses scientific data to support any advertising or labeling claims we make concerning our products, although no pre-clearance or filing is required to be made with either agency. If we are unable to provide the required support for such claims, the FTC may stop us from making such claims or require us to stop selling the affected products.
If we are unable to protect our intellectual property or if we infringe the intellectual property of others, our financial condition and future prospects could be materially harmed.
          We rely significantly on the protections afforded by patent and trademark registrations that we routinely seek from the U.S. Patent and Trademark Office (“USPTO”) and from similar agencies in foreign countries. We cannot be certain that any patent or trademark application that we file will be approved by the USPTO or foreign agencies. In addition, we cannot be certain that we will be able to successfully defend any trademark, trade name or patent that we hold against claims from, or use by, competitors or other third parties. No consistent policy has emerged from the USPTO or the courts regarding the breadth of claims allowed or the degree of protection afforded under biotechnology and similar patents. Our future success will depend, in part, on our ability to prevent others from infringing on our proprietary rights, as well as our ability to operate without infringing upon the proprietary rights of others. We may be required at times to take legal action to protect our proprietary rights and, despite our best efforts, we may be sued for infringing on the patent rights of others. Patent litigation is costly and, even if we prevail, the cost of such litigation could adversely affect our financial condition. If we do not prevail, in addition to any damages we might have to pay, we could be required to stop the infringing activity or obtain a license. We cannot be certain that any required license would be available to us on acceptable terms, or at all. If we fail to obtain a license, our business could be materially adversely affected. In addition to seeking patent protection, we rely upon a combination of non-disclosure agreements, other contractual restrictions and trade secrecy laws to protect proprietary information. There can be no assurance that these steps will be adequate to prevent misappropriation of our proprietary information or that our competitors will not independently develop technology or trade secrets that compete with our proprietary information or know-how.

13


Table of Contents

Under our current business model, we do not have manufacturing capabilities of our own.
          We outsource all of our product manufacturing and packaging operations under our current business model. As a result, we do not have the physical or human resources to independently manufacture our Zicam, Nasal Comfort, and Xcid products or any other products that we may develop. If we are unable to enter into cost-effective or otherwise suitable arrangements for manufacturing our Zicam products or any other products, or if our third-party contractors fail to adequately perform their manufacturing operations, experience problems with product quality or regulatory compliance, or timeliness of product delivery, our sales and related financial results could be materially adversely affected. If, in the future, we decide to establish our own manufacturing facilities, we will require substantial additional funds and significant additional personnel to undertake such operations. We cannot be certain that such funding or a sufficient number of such qualified persons will be available for such an undertaking.
We may pursue strategic acquisitions of technologies, products, and/or brands, which involve a variety of costs, and we may not realize the anticipated benefits of such acquisitions.
          We may pursue strategic acquisitions to acquire delivery technologies, brands, and products that would allow us to leverage our operating model. We have limited experience in identifying and consummating acquisitions. Additionally, acquisitions typically have many risks, including: unanticipated integration costs and delays; potentially substantial indebtedness; and diversion of management’s attention. If we are not able to successfully integrate an acquisition, we may incur substantial charges that could adversely affect our results of operations.
We may experience product backlogs.
          We have established inventory plans to support sales expectations for all of our products. However, we cannot be certain that these measures will be sufficient to prevent backlogs of product availability in the future. Any such future backlogs will potentially result in higher production costs, higher freight costs to expedite shipment of raw materials and finished goods, fines from certain retailers, cancelled orders and lost revenue. These in turn could materially affect our results of operations and financial condition.
Loss of key personnel could have a material adverse effect on our operations and financial results.
          We have a limited number of employees and our success depends on the continued services of our senior management and key employees as well as our ability to attract additional members to our management team with experience in the consumer health products industry. The unexpected loss of the services of any of our management or other key personnel, or our inability to attract new management when necessary, could have a material adverse effect upon our operations and financial results.
To protect against various potential liabilities, we maintain a variety of insurance programs. Significant increases in the cost or decreases in the availability of such insurance could adversely impact our financial condition.
          We maintain insurance, including property, general and product liability, and directors’ and officers’ liability, to protect against potential loss exposures. In addition to the risks associated with product liability insurance discussed above, we cannot predict whether deductible or retention amounts associated with all of our insurance programs will increase, or whether insurance coverage, generally speaking, will be reduced in the future. To the extent that losses occur, there could be an adverse affect on our financial results depending on the nature of the loss and the level of insurance coverage we have maintained. From time to time, we may reevaluate and change the types and levels of insurance coverage that we purchase.
Our Board of Directors is authorized to issue shares of preferred stock that could have rights superior to our outstanding shares of common stock and, if issued, could adversely impact the value of our common stock.
          Our certificate of incorporation permits our Board of Directors, in its sole discretion, to issue up to 2,000,000 shares of authorized but unissued preferred stock. These shares may be issued by our Board without further action by our shareholders, and may include any of the following rights (among others) as our Board may determine, which rights may be superior to the rights of our outstanding common stock:

14


Table of Contents

    voting rights, including the right to vote as a class on particular matters;
 
    preferences as to dividends and liquidation rights;
 
    conversion rights;
 
    anti-dilution protections; and
 
    redemption rights.
          Since our Board of Directors has the authority to determine, from time to time, the terms of our authorized preferred stock, there is no limit on the amount of common stock that could be issuable upon conversion of any future series of preferred stock that may be issued. The rights of holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock that may be issued in the future. In addition, the market price of our common stock may be adversely affected by the issuance of any series of preferred stock with voting or other rights superior to those of our common stock. The issuance of any series of preferred stock could also have the effect of making it more difficult for a third party to acquire a majority of our outstanding common stock.
The price of our stock may continue to be volatile.
          The market price of our common stock, which is quoted for trading on the Nasdaq Global Select Market, has been highly volatile and may continue to be volatile in the future. Any one, or combination, of the following factors could cause the market value of our common stock to decline quickly: operating results that differ from market expectations; negative or other unanticipated results of clinical trials or other testing; delays in product development; technological innovations or commercial product introductions by our competitors; lack of timely availability of product or inventory; changes in government regulations; developments concerning proprietary rights, including pending or threatened patent litigation; public concerns regarding the safety of any of our products or any recall of our products; the outcome of litigation against the Company; and general economic and stock market conditions. The stock market has experienced, and it may continue to experience, significant price and volume fluctuations. Historically, these fluctuations particularly affect the market prices of equity securities of small capitalization companies like Matrixx. Often, the effect on the price of such securities is disproportionate to the operating performance of such companies. In our case, such fluctuations may adversely affect our stockholders’ ability to dispose of our shares at a price equal to or above the price at which they purchased such shares.
We have agreed to indemnify our officers and directors from liability.
          Our Certificate of Incorporation requires us to indemnify our officers and directors who are or were made a party to, or are or were threatened to be made a party to, any threatened, pending, or completed action, suit or proceeding because he or she is or was a director or officer of the Company. These provisions require us to advance expenses to an indemnified party in connection with defending any such proceeding, upon receipt of an undertaking by the indemnified party to repay those amounts if it is later determined that the party is not entitled to indemnification. These provisions may also reduce the likelihood of derivative litigation against directors and officers and discourage or deter stockholders from suing directors or officers for breaches of their duties to us, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, to the extent that we expend funds to indemnify directors and officers, funds will be unavailable for operational purposes.
ITEM 1B. UNRESOLVED STAFF COMMENTS
          None
ITEM 2. PROPERTIES
          In March 2008, we entered into a five-year renewable lease for corporate office and research and development space, comprising approximately 23,000 square feet, at 8515 E. Anderson Drive, in Scottsdale, Arizona. The new facility combines our corporate office and research and development activities in one building and

15


Table of Contents

increases our laboratory capabilities. In December 2006, we entered into a five year cancelable lease for a research and development facility in Phoenix, Arizona. We are continuing to lease that facility in Phoenix, Arizona and are evaluating options to sublease the space or terminate the lease. We recently consolidated to one warehouse and warehouse storage and shipping of our finished goods are provided by a contract warehouse in Plainfield, Indiana through a month-to-month agreement.
ITEM 3. LEGAL PROCEEDINGS
     Litigation
     The Company is involved in various product liability claims and other legal proceedings. The Company’s legal expense for defense of these lawsuits continues to have a significant impact on the results of operations as the Company defends itself against the various claims.
     Among the principal matters pending to which the Company is a party are the following:
Product Liability Matters
     General. Numerous lawsuits have been filed against us alleging that our Zicam Cold Remedy nasal gel product has caused the permanent loss or diminishment of the sense of smell or smell and taste. As discussed in greater detail below, we believe these allegations are unfounded. The Company is incurring significant legal expense for defense of these lawsuits. For the fiscal year ended March 31, 2008, litigation expense decreased to approximately $2.5 million (net of $560,000 for insurance reimbursements), compared to $4.2 million for the twelve months ended March 31, 2007 (net of $1.6 million for insurance reimbursements). For the three-month transition period ended March 31, 2007, litigation expense was approximately $1.0 million, reduced by reimbursement of approximately $1.6 million from our insurance carriers for litigation expense incurred prior to 2006. For the fiscal year ended December 31, 2006, litigation expense was approximately $6.0 million. In the fiscal year ended December 31, 2005, litigation expense was $6.2 million, reduced by reimbursement of approximately $2.0 million from our principal insurance carrier, resulting in net legal expense of approximately $4.2 million. We do not expect to realize any sizable reimbursements from our insurance carriers for legal expenses incurred in fiscal 2009 or any future periods.
     From December 31, 2007 through May 30, 2008, four new product liability cases were filed against the Company and four product liability cases were dismissed or are pending dismissal either as a result of successful Company motions or through the settlement of cases for immaterial amounts. Additionally, beginning on March 25, 2008, the case, Bruno vs. Matrixx Initiatives, Inc. (filed July 7, 2006, in the Superior Court of the State of California, County of San Diego, Case No. 868821), was tried before a jury. On April 3, 2008 the jury delivered a unanimous verdict in favor of the Company. The following chart discloses the number of outstanding product liability cases (excluding those cases that have been settled but not yet dismissed) and associated plaintiffs at the indicated dates:
                                 
    Dec. 31, 2005   Dec. 31, 2006   March 31, 2007   May 30, 2008
Number of Pending Cases
    50       25       27       16  
Number of Plaintiffs
    427       36       41       29  
     Two of the pending lawsuits were filed as class action lawsuits covering named and unnamed plaintiffs. Various defendants in the lawsuits, including manufacturers and retailers, have received indemnification or other recovery from us for damages related to the lawsuits.
     Settlement of Arizona Consolidated Litigation. On January 19, 2006, we entered into an agreement to settle claims made by approximately 90% of the plaintiffs (approximately 340 individuals) in all of the Zicam Cold Remedy product liability lawsuits pending against the Company at that time. This settlement related to the Arizona consolidated litigation, In Re Consolidated Zicam Product Liability Cases, Superior Court of Arizona (Maricopa County). The settlement documents acknowledge that Matrixx has denied and continues to deny any liability to the plaintiffs. Those plaintiffs who were eligible and elected to participate in the settlement program dismissed their

16


Table of Contents

claims with prejudice and provided written releases of their claims against the Company in return for their participation. Of the plaintiffs who did not participate in the settlement program, all have dismissed their claims. Matrixx paid $11.9 million to fund awards to be made under the settlement program. In addition, Matrixx paid $100,000 to cover the administration of the settlement program by plaintiffs’ counsel. The Company recognized a charge of approximately $4.3 million (after tax) in the fourth quarter of 2005 to cover the portion of the settlement program costs not covered by insurance.
     Cases Dismissed Subsequent to December 31, 2007 (Federal Courts). The following federal court cases against the Company were dismissed subsequent to December 31, 2007:
             
Date Filed   United States District Court   Named Plaintiff   Date Dismissed
June 6, 2007
  Eastern District, Tennessee   Newman   February 22, 2008
April 27, 2007
  West Virginia   Seckman   March 6, 2008
January 14, 2005
  Oregon   Lusch   May 22, 2008
October 29, 2004
  Central District, California, on appeal to Ninth Circuit Court of Appeals   O’Hanlon   June 4, 2008
     Federal law and the law of many states require that the testimony of a scientific or medical expert witness be reliable and based on valid scientific data and analysis before it can be allowed into evidence. To date, the Company has submitted motions in eight federal lawsuits against the Company challenging the reliability and admissibility of the testimony of expert witnesses who claim that Zicam is capable of causing or has caused smell and taste loss. To date, the courts have ruled on all eight motions. Each court has ruled that the testimony of the plaintiffs’ experts lacks reliability and a sufficient scientific basis for admission into evidence. The eight cases in which orders have been granted are: Hans, et al. vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Western District of Kentucky); Salden vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Eastern District of Michigan); Sutherland vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Northern District of Alabama); Benkwith vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Middle District of Alabama); O’Hanlon vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Central District of California); Hilton vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Northern District of Texas); Wyatt vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Northern District of Alabama); and Lusch v. Matrixx Initiatives, Inc., et al. (United States District Court for the District of Oregon). A dismissal with prejudice has been entered in all eight cases. The plaintiffs in the O’Hanlon case filed an appeal, which was settled by the Company for an immaterial amount and dismissed accordingly by the Ninth Circuit Court of Appeals on June 6, 2008.
     Cases Dismissed Subsequent to December 31, 2007 (State Courts). The following state court case against the Company was dismissed subsequent to December 31, 2008:
             
Date Filed   Court   Named Plaintiff   Date Dismissed
July 7, 2006
  County of San Diego, California   Bruno   April 3, 2008
     Pending Cases as of May 30, 2008 (Federal Courts). The following federal court cases remain pending against the Company, covering approximately seven plaintiffs:
         
Date Filed   United States District Court   Named Plaintiff
July 12, 2007
  Eastern District, Washington   Ballew
April 25, 2008
  Eastern District, Louisiana   Ehtheridge
March 1, 2007
  Middle District, Florida   Evans
May 16, 2007
  Western District, Tennessee   Rose
February 29, 2008
  Middle District of Louisiana   Carter

17


Table of Contents

     Pending Cases as of May 30, 2008 (State Courts). The following state court cases remain pending against the Company, covering approximately 22 plaintiffs:
         
Date Filed   Court   Named Plaintiff
February 15, 2008
  Fairfax County, Virginia   Adler
May 4, 2007
  Maricopa County, Arizona   Brierly
March 17, 2008
  Broward County, Florida   Bunin
February 24, 2006
  Niagara County, New York   Campbell
January 13, 2005
  Fresno County, California   Cash
April 14, 2004
  Broward County, Florida   Hood
October 31, 2007
  Maricopa County, Arizona   Medel
June 5, 2006
  Oklahoma County, Oklahoma   Stark
November 3, 2006
  Maricopa County, Arizona   Poole
March 27, 2007
  Cook County, Illinois   Skender
August 30, 2006
  Los Angeles County, California   Stanley
     Potential Claimants. The Company has been advised that certain plaintiffs’ attorneys collectively represent approximately 500 additional potential claimants for whom they have not yet filed lawsuits. The Company is in the process of determining the number of potential claimants, the nature or basis of their purported claims, and when or if the potential claimants will ultimately file one or more lawsuits against the Company.
     Plaintiffs’ law firms may continue to solicit potential claimants and, as a result, additional lawsuits may be filed against us. We cannot predict the outcome of the litigation but we will defend ourselves vigorously. If any liability were to result from one or more of these or future lawsuits, we believe our financial results could be materially impacted. Our financial results also could be materially impacted by the adverse publicity that may result from the lawsuits.
     Company’s Position Regarding the Allegations. Matrixx continues to believe that Zicam Cold Remedy nasal gel does not cause loss of smell and that claims to the contrary are scientifically unfounded and misleading. The Company believes that upper respiratory infections and nasal and sinus disease are the causes of the smell dysfunctions reported by some consumers. One of the most common causes of smell disorders is the cold itself, the very condition the product is used to treat. Other causes are sinusitis and rhinitis, conditions which are sometimes present when the product is used. The Company’s position is supported by cumulative science, and it has been confirmed by a multi-disciplinary panel of scientists.
     Scientific Advisory Board. We convened a Scientific Advisory Board to review claims that use of Zicam Cold Remedy nasal gel spray can lead to the diminishment or loss of sense of smell. The Advisory Board is comprised of medical doctors and researchers who are independent of the Company. Matrixx provided honorariums for members’ attendance at meetings, travel expenses, and funded grants to design and perform research studies investigating the contention that Zicam Cold Remedy zinc gluconate nasal gel is associated with disorders of smell.
     In February 2004, the Advisory Board initially reviewed the claims and found that the allegation was largely anecdotal and based on unsupported analogies and generally appeared to lack scientific merit. However, in an effort to further explore the issues, the Advisory Board and the Company designed and had performed studies to (1) better assess the causes of smell loss and the rate at which smell loss occurs; (2) determine whether any substantial amount of the nasal gel interacts with the smell tissue located at the very top portion of the nasal cavity; and (3) evaluate through animal experiments how much Zicam would be needed to have any effect on smell function.
     In 2004 and 2005, the studies designed by the Advisory Board were conducted and completed. After reviewing the data, the Advisory Board unanimously concluded that the cumulative scientific evidence failed to support the suggestion that Zicam use is associated with impairment of the senses of smell and taste. Rather, the evidence confirms that the major causes of smell loss are upper respiratory infection and nasal and sinus disease, all of which are ever-present in the population of Zicam users. None of the Zicam gel approaches the smell tissue when Zicam is

18


Table of Contents

used as directed, and there is only scant and questionable evidence that even trace amounts can reach the upper nasal cavity when the product is egregiously misused.
     Insurance. We submit lawsuits to our insurance carriers when applicable. In April 2004, we established a fully-funded deductible insurance program through a product liability insurance carrier. The settlement of the consolidated Arizona litigation exhausted this insurance program. In April 2006, we replaced the self-funded program with a limited traditional insurance program. This insurance program does not cover previously existing lawsuits and only applies to any new claims made after it became effective. We do not expect any additional reimbursements from our insurance carriers for legal expenses incurred in fiscal 2009 or any future periods to be sizable.
Litigation Reserves
     As of December 31, 2005, the Company established a reserve of $1.3 million for any future payment of settlement or losses related to the cold remedy litigation. This reserve was based on certain assumptions, some of which are described below, and was the amount, excluding defense costs, the Company believed it could reasonably estimate would be spent to resolve the remaining cases that had been filed. Some of the significant factors that were considered in the establishment of the reserve were as follows: the actual costs incurred by the Company up to that time in resolving several claims; the development of the Company’s legal defense strategy and structure in light of the Arizona settlement; and the number of cases that remained pending against the Company. There are events, such as the dismissal of any cases, the filing of new lawsuits, threatened claims, the outcome of a trial, or rulings on pending evidentiary motions, that may have an impact on the Company’s conclusions as to the adequacy of the reserve for the pending product liability lawsuits. Litigation is inherently unpredictable and excessive verdicts do occur. Although we believe we have substantial defenses in these matters, we could in the future incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period. The Company regularly reviews this reserve and may make adjustments based on the number of pending, settled, and threatened cases, as well as continuing legal defense strategy. The reserve was approximately $1.1 million and $1.0 million as of March 31, 2008 and March 31, 2007, respectively. The Company will continue to review the adequacy of the associated reserve on a quarterly basis.
Securities Litigation Matters
     Two class action lawsuits were filed in April and May 2004 against the Company, our President and Chief Executive Officer, Carl J. Johnson, and our Executive Vice President and Chief Financial Officer, William J. Hemelt, alleging violations of federal securities laws. On January 18, 2005, the cases were consolidated and the court appointed James V. Sircusano as lead plaintiff. The amended complaint also includes our Vice President of Research and Development, Timothy L. Clarot, as a defendant and was filed March 4, 2005. The consolidated case is Sircusano, et al. vs. Matrixx Initiatives, Inc., et al., in the United States District Court, District of Arizona, Case No. CV04-0886 PHX DKD. Among other things, the lawsuit alleges that between October 2003 and February 2004, we made materially false and misleading statements regarding our Zicam Cold Remedy product, including failing to adequately disclose to the public the details of allegations that our products caused damage to the sense of smell and of certain of the product liability lawsuits described above. We filed a motion to dismiss this lawsuit and, on March 8, 2006, the Company received an Order dated December 15, 2005 granting the motion to dismiss the case, without prejudice. On April 3, 2006, the plaintiff appealed the Order to the United States District Court of Appeals, Ninth Circuit, Case No. 2:04-CV-886, and we are awaiting a schedule for oral argument by the Ninth Circuit Court. In accordance with and subject to the provisions of the Company’s Certificate of Incorporation, Messrs. Johnson, Hemelt, and Clarot will be indemnified by the Company for their expenses incurred in defending these lawsuits and for any other losses which they may suffer as a result of these lawsuits. The Company has submitted this matter to its insurance carriers and may incur charges up to the deductible amount of $1 million. If any liability were to result from this lawsuit that is not covered by insurance, we believe our financial results could be materially impacted.

19


Table of Contents

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
     No matter was submitted to a vote of our security holders during the quarter ended March 31, 2008, through the solicitation of proxies or otherwise.
Executive Officers of Matrixx
     The names, ages, positions and business experience of each of our executive officers are listed below. Each executive officer is elected by our Board of Directors to hold office until his or her successor is appointed and qualified or until such earlier time as such officer may resign or be removed by the board.
Carl J. Johnson, 59, President and Chief Executive Officer
     Mr. Johnson joined Matrixx in July 2001 as President and Chief Executive Officer and as a member of the Board of Directors. Mr. Johnson’s professional experience exceeds 35 years in the product development, marketing, and sales arenas with several large pharmaceutical and consumer goods companies. From 1993 to 2001, Mr. Johnson was Vice President, Commercial Development with Perrigo Company, a public company and leading manufacturer of over-the-counter pharmaceutical and nutritional products for the store brand market. In that capacity he was responsible for procuring new products and technologies and contract manufacturing services emphasizing Abbreviated New Drug Applications (ANDA) products. Mr. Johnson also worked at Johnson & Johnson from 1973 to 1989 where he held a number of high level marketing and sales positions, including responsibility for the national launch of the Acuvue® disposable contact lens product. Mr. Johnson also provided marketing leadership for a special team tasked to re-engineer Johnson & Johnson’s sales, administrative and operational functions. Mr. Johnson earned a Master of Business Administration — Marketing from the Fairleigh Dickinson University and a Bachelor of Science in Economics from Wagner College.
William J. Hemelt, 54, Executive Vice President and Chief Financial Officer
     Mr. Hemelt joined Matrixx in June 1998 as our Chief Financial Officer, Treasurer, and Secretary. Mr. Hemelt served as Secretary until February 2005. From 1980 to 1997, Mr. Hemelt held a variety of financial positions with Arizona Public Service Company, Arizona’s largest utility, including six years as Treasurer and four years as Controller. Mr. Hemelt earned a Master of Business Administration and a Bachelor of Science in Electrical Engineering from Lehigh University.
Timothy L. Clarot, 53, Vice President of Research & Development
     Mr. Clarot joined Matrixx in 1999 and became Director of Operations in 2001, overseeing our manufacturing and distribution processes and development of new products. In June 2003, Mr. Clarot was named Director, Research and Development. Mr. Clarot was promoted to Vice President, Research and Development in January 2004. Mr. Clarot oversees product-related regulatory compliance activities, product development and consumer affairs. From 1981 to 1998, Mr. Clarot held positions of increasing responsibility, including Quality Control Manager, with Reckitt Benckiser, a world leader in consumer products. Mr. Clarot holds a Bachelor of Science in Chemistry from California State University at Fresno.
Timothy J. Connors, 45, Vice President of Marketing
Mr. Connors joined Matrixx in July 2005 as Director of National Sales and was promoted to Vice President of Marketing in June, 2007. Prior to joining Matrixx, he was a partner for a consulting firm helping numerous consumer products and healthcare organizations, foreign and domestic, to successfully introduce new companies and brands into the marketplace. Mr. Connors started his career working for Nestle Foods, Benckiser, and The Clorox Company in a variety of sales and marketing assignments. He is responsible for leading the Company’s overall marketing strategy and will focus his efforts on increasing Zicam’s market share and introducing Matrixx’s new product lines. Mr. Connors holds a Bachelors of Arts degree in Marketing from Penn State University.

20


Table of Contents

Samuel Cowley, 48, Executive Vice President, Business Development, General Counsel and Secretary
     Mr. Cowley was elected to the Matrixx board of directors in July 2005. In May 2008, Mr. Cowley joined the Company as Executive Vice President, Business Development, General Counsel and Secretary. Previously, Mr. Cowley served until May 2007, as Executive Vice President and General Counsel for Swift Transportation Co., Inc. and was a member of Swift’s Board of Directors. Prior to joining Swift in March 2005, Mr. Cowley had been a practicing attorney with the law firm of Snell & Wilmer L.L.P., Phoenix, Arizona since March 1990. Mr. Cowley’s practice was concentrated in mergers and acquisitions, securities regulation, including Sarbanes-Oxley Act compliance, and corporate finance. Previously, he was associated with Reid & Priest, New York, New York. Mr. Cowley is a graduate of Cornell Law School, Ithaca, New York and of Brigham Young University, Provo, Utah with a B.A. in Economics. Mr. Cowley is admitted to practice law in the States of Arizona and New York.
James A. Marini, 46, Vice President of Sales
     Mr. Marini joined Matrixx in July 1997 as National Sales Manager and was promoted to Vice President of Sales in January 2004. Mr. Marini has directed the introduction and development of the national sales program for Zicam Cold Remedy since 1999. Mr. Marini is responsible for Matrixx’s sales efforts and oversight of our sales force and contract broker network. From 1977 to 1997 Mr. Marini held a variety of positions with Dominos Supermarkets in New York, including six years as Vice President. Mr. Marini attended Mercy College.
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
     Our common stock has been quoted for trading on the Nasdaq Global Select Market (previously known as Nasdaq National Market) since April 24, 1996. From then until June 19, 2002, our stock traded under the symbol “GUMM.” Effective on June 20, 2002, in connection with our name change to Matrixx Initiatives, Inc., our stock trading symbol changed to “MTXX.” The following table sets forth, for the periods indicated, the range of high and low prices of our common stock as reported by the Nasdaq Global Select Market.
                     
        Market Price
    Quarter Ended   High   Low
Fiscal Year 2006
                   
First Quarter
  March 31, 2006   $ 26.22     $ 19.68  
Second Quarter
  June 30, 2006   $ 23.46     $ 12.78  
Third Quarter
  September 30, 2006   $ 19.19     $ 14.15  
Fourth Quarter
  December 31, 2006   $ 22.96     $ 15.49  
 
                   
Transition Period 2007
  March 31, 2007   $ 18.89     $ 13.89  
 
                   
Fiscal Year 2008
                   
First Quarter
  June 30, 2007   $ 21.07     $ 15.89  
Second Quarter
  September 30, 2007   $ 21.50     $ 17.83  
Third Quarter
  December 31, 2007   $ 20.43     $ 13.78  
Fourth Quarter
  March 31, 2008   $ 16.50     $ 10.17  
     As of March 31, 2008, we had approximately 4,050 record and beneficial stockholders.
Dividend Policy
     Since our initial public offering in 1996, we have not paid dividends on our common stock and do not expect to pay dividends in the foreseeable future. The amount of future dividends, if any, will be determined by the Board of

21


Table of Contents

Directors based upon our earnings, financial condition, capital requirements and other factors, including any contractual or statutory restrictions on our ability to pay dividends. In addition, under the terms of our credit facility with Comerica Bank, as long as we have any outstanding loan balance or other obligations under the credit facility, we cannot pay any dividend without Comerica Bank’s consent.
Stock Performance Graph
     The following graph compares our cumulative total stockholder return with those of the Nasdaq Stock Market Index and the Russell 2000 Growth Index for the five fiscal years ended March 31, 2008. The graph assumes that $100 was invested on March 31, 2003 in (1) our Common Stock, (2) the Nasdaq Stock Market Index, and (3) the Russell 2000 Growth Index, including in each case, if applicable, reinvestment of dividends. Note: We caution that the stock price performance shown in the graph below should not be considered indicative of potential future stock price performance.
(PERFORMANCE GRAPH)
                         
PERFORMANCE TABLE
Date   Matrixx   Nasdaq   Russell 2000 Growth
3/31/2003
    100.00       100.00       100.00  
3/31/2004
    123.73       147.60       163.16  
3/31/2005
    155.97       148.59       164.59  
3/31/2006
    320.99       175.22       210.40  
3/31/2007
    222.91       181.75       213.70  
3/31/2008
    200.82       169.51       238.94  
     This Nasdaq index comprises all domestic shares traded on the NASDAQ Global Select, NASDAQ Global Market, and The NASDAQ Capital Market, excluding preferred, rights and warrants. The Russell 2000 Growth Index is a growth industry index that measures the performance of the 2,000 smallest companies in the Russell 3000 Index with the highest, proportionately weighted, growth.

22


Table of Contents

Issuer Purchases of Equity Securities
     The following table provides information about purchases by the Company (and its affiliated purchasers) during the quarter ended March 31, 2008 of equity securities that are registered by the Company pursuant to Section 12 of the Exchange Act.
Issuer Purchases of Equity Securities
                                 
                    Total Number of    
                    Shares Purchased as   Maximum Number of
    Total Number           Part of Publicly   Shares that May Yet be
    of Shares   Average Price   Announced Plans or   Purchased Under the
Period   Purchased   Paid per Share   Programs   Plans or Programs
1/01/08-1/31/08
    103,750     $ 13.14       367,844       632,156  
2/01/08-2/28/08
    151,268     $ 13.05       519,112       480,888  
3/1/08-3/31/08
    15,189     $ 14.64       534,301       465,699  
Total
    233,194     $ 13.09       534,301       465,699  
     In April 2004, the Company’s Board of Directors authorized a Common Stock Repurchase Program for up to 1.0 million shares of the Company’s common stock. During fiscal 2008, the Company purchased 493,969 shares of common stock on the open market at an aggregate cost of $7,148,245. In addition, the Company withheld (repurchased) 22,432 shares of common stock, at an aggregate cost of $315,148, from employees and directors to satisfy tax withholding requirements associated with vested restricted stock. The Company did not repurchase any of its common stock during the three months ended March 31, 2007 or during calendar year 2006 or 2005.
ITEM 6. SELECTED FINANCIAL DATA
     The following table sets forth selected historical financial data for Matrixx for the fiscal year ended March 31, 2008, the three-month transition period ended March 31, 2007 and the previous four fiscal years ended December 31, 2006, 2005, 2004, and 2003. The financial data presented below is derived from Matrixx’s audited consolidated financial statements. We report Matrixx’s, Zicam, LLC’s, Zicam Swab Products, LLC’s, Zicare LLC’s, and Zicam Canada, Inc.’s financial results on a consolidated basis. For additional information, see the financial statements of Matrixx and the notes thereto included elsewhere in this report. The following table should be read in conjunction with Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and is qualified by reference thereto and to Matrixx’s financial statements and notes thereto.
                                                 
            Transition Period    
    Fiscal Year   Three Months    
    Ended March 31,   Ended March 31,   Fiscal Years Ended December 31,
(000’s, except share data)   2008   2007   2006   2005   2004   2003
Net sales
  $ 100,972     $ 19,046     $ 96,231     $ 90,461     $ 60,231     $ 43,496  
Net income
  $ 10,428     $ 1,709     $ 4,927     $ 3,078     $ 4,957     $ 3,344  
 
                                               
Net income per share of common stock — basic
  $ 1.07     $ 0.18     $ 0.51     $ 0.32     $ 0.52     $ 0.36  
Net income per share of common stock — diluted
  $ 1.04     $ 0.17     $ 0.49     $ 0.32     $ 0.52     $ 0.35  
Dividends per share
  $     $     $     $     $     $  
Shares outstanding at period end
    10,175       10,079       9,948       9,600       9,520       9,475  
Total assets
  $ 78,149     $ 71,151     $ 85,107     $ 86,442     $ 60,134     $ 50,077  
Long term obligations
  $     $     $     $     $     $  
Stockholders’ equity
  $ 65,552     $ 60,435     $ 58,087     $ 48,110     $ 44,126     $ 38,790  
Earnings for 2005 include the recording of $8.5 million for expense related to settling litigation ($12.0 million settlement plus $1.3 million for litigation reserves, less $4.8 million of insurance reimbursement).

23


Table of Contents

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Executive Summary
     The Company develops, produces, markets and sells innovative, over-the-counter (OTC) healthcare products with an emphasis on those that utilize unique, novel and/or proprietary delivery systems that provide consumers with “Better Ways to Get Better®”. The Company currently markets its products within the $4.0 billion overall cough and cold category at retail. Our Zicam products are sold in the cold (2 nasal delivery products and 5 oral delivery products), allergy/sinus (3 Zicam nasal delivery), cough (cough spray and RapidMelt tablets), and multi-symptom relief (4 oral delivery products) market groups of the overall cough and cold category. Our Nasal Comfort products are generally sold within the space allocated for allergy and sinus products at retail. We expect that our mix of products sold will change due to seasonality and varying growth rates within the market groups. Our products are currently available at all of the major food, drug, and mass merchant retailers.
     The following table details our sales by product class, for the periods indicated, with further details below:
                                                                 
    12 months ended           12 months ended           12 months ended           12 months ended    
Product Class   March 31, 2008   %   March 31, 2007   %   December 31, 2006   %   December 31, 2005   %
Cold Remedy
  $ 68,225,508       68 %   $ 69,093,132       71 %   $ 69,046,345       72 %   $ 55,292,673       61 %
Allergy/Sinus/Nasal Comfort
    17,325,720       17 %     16,109,489       17 %     15,468,683       16 %     20,163,688       23 %
Cough
    4,461,208       4 %     6,143,165       6 %     6,059,285       6 %     6,514,769       7 %
Multi-Symptom Cold/Flu
    10,607,287       11 %     6,254,790       6 %     5,656,467       6 %     8,489,465       9 %
Antacid
    352,661       0 %             0 %             0 %             0 %
 
                                                               
Total Net Sales
  $ 100,972,384       100 %   $ 97,600,575       100 %   $ 96,230,780       100 %   $ 90,460,595       100 %
 
     Because of the extreme seasonality of our business, our Board of Directors approved a change in our fiscal year in order to better align our operations and financial results with the entire cold season (our previous fiscal years ended in the middle of the cold season). Due to the change in our fiscal year, the three months ended March 31, 2007, are reported as a transition period. Our new fiscal year began April 1, 2007 and ended March 31, 2008. As in prior years, we believe the quarter ending June 30th (our new fiscal first quarter) will result in a net loss.
     Net sales for the fiscal year ended March 31, 2008 increased to approximately $101.0 million, or 3% above net sales of $97.6 million for the twelve months ended March 31, 2007. The increase in net sales is primarily attributable to sales of our new multi-symptom relief products, which began shipping during our fiscal second quarter (ended September 30, 2007). Sales of allergy/sinus products grew $1.2 million, or 8%, during the year, while sales of our cough products declined $1.7 million, or 27%, compared to the comparable period in the prior year. The decrease in sales of cough products relates to the discontinuation of several of the original cough spray products. During fiscal 2008, we experienced a change in inventory management practices with certain of our large national retailers. This change reduced the amount of inventory these retailers carried, as well as the size of pre-season inventory purchases, compared to prior years. We anticipate retailers will continue to improve their inventory management practices and we expect our sales to retailers will more closely mirror retail sales of our products to consumers. We expect the Zicam brand will continue to grow as we grow consumer awareness of our products, increase distribution of our products, and introduce new items.
     Net income for the fiscal year ended March 31, 2008 was approximately $10.4 million compared to approximately $6.5 million for the twelve months ended March 31, 2007. The increase in net income is primarily attributable to a decrease in selling, general and administrative (SG&A) expense and, to a lesser degree, higher net sales. The decreased SG&A expense was related to reductions in legal expense related to product liability litigation (see Item 3 — Legal Proceedings). Product liability defense costs decreased to $2.5 million (net of $560,000 for insurance reimbursements) for the fiscal year ended March 31, 2008, compared to $4.2 million for the twelve months ended March 31, 2007 (net of $1.6 million for insurance reimbursements). We anticipate legal defense costs will be $500,000 to $750,000 per quarter during fiscal 2009.

24


Table of Contents

     We expect net income (loss) in future periods to be significantly affected by the level of sales, the timing and amount of our advertising, research and development expenses, and the timing and amount of expenses incurred in defense of product liability litigation matters. Expenditures for advertising and research and development will vary by quarter throughout the year and could be significantly different in future periods than the amounts incurred in the same period in earlier years. We expect that advertising expenses will be highest during the cold season (third and fourth fiscal quarters). We anticipate quarterly earnings will continue to vary along with the seasonality of sales and the level of marketing and research and development expense. As in prior years, we expect to report a loss in the quarter ending June 30.
     The Company’s management reviews several key indicators in evaluating overall performance:
  1)   We compare our year-to-date sales and net income performance against our stated annual goal for each. For fiscal 2008, our goal was to grow sales 5% to 15% above the $97.6 million recorded for the trailing twelve months ended March 31, 2007 ($102.5 million — $112.25 million), and to increase net income to the range of $9.3 million to $10.8 million, compared to $6.5 million for the twelve months ended March 31, 2007. However, the 2007/2008 cold season had an unusually slow start and the incidence of colds and flu in the general population was tracking at the lowest levels since Zicam was introduced in 1999. We believe the change in inventory management practices by certain customers, the slow start to the cold season, and the low level of illness is reflected in the lower level of sales growth (3%) realized during the year. Due to decreased SG&A expense, we realized net income of $10.4 million in fiscal 2008, which was in line with our original goal.
 
  2)   We monitor our share of the cough and cold market. For the 52 weeks ended March 23, 2008, retail sales of our products (as measured by three outlet syndicated scanner data, not including our largest customer, Wal-Mart) increased approximately 9% over the comparable period in the previous year, while the entire cough and cold category increased approximately 4% over the same period. The increased sales of our products for the 52 weeks ended March 23, 2008 resulted in Zicam products achieving a 2.9% dollar share of the category versus 2.8% in the prior year period.
 
  3)   We measure our ability to maintain strong gross margins on our products. During fiscal 2008, we realized an average gross margin of 66%, comparable to the 66% average gross margin achieved in the twelve months ended March 31, 2007, but below our goal of 69% to 70% (gross margins on our existing products vary between 55% and 80%). Average gross margins were negatively impacted by returns of discontinued items and the mix of products sold, primarily related to sales of our new multi-symptom products that are sold at prices below our cold remedy and allergy/sinus products. We are attempting to identify ways to improve gross margin on the new multi-symptom products in the future. Additionally, average gross margins were negatively impacted by a $1.1 million increase to our inventory reserve in excess of our customary amount, to account for expiring products and obsolete components.
 
  4)   We evaluate our operating performance by reviewing, over time, our ability to decrease selling, general and administrative expenses as a percentage of net sales. For the fiscal year ended March 31, 2008, our operating expenses (excluding R&D and product liability litigation related charges) were approximately 44% of our net sales compared to 47% in the twelve months ended March 31, 2007.
 
  5)   We review the distribution and mix of our products by key national retailers. Our ten largest retail customers account for a substantial majority of our annual sales, and we encourage our largest customers to carry a mix of our highest-selling products. Retailers generally reset their cough and cold sections during the third calendar quarter of each year, at which time they add new products. We encourage retailers to replace discontinued items with new Zicam products.
Seasonality and Quarterly Results
     The products we currently market are seasonal in nature, and sales at retail generally increase as the level of population suffering from colds rises. The Company records sales when we ship products from our warehouse facilities. During the second fiscal quarter, the Company usually realizes increased sales volume as retailers stock

25


Table of Contents

our products and order displays to prepare for the upcoming cough and cold season. Additional sales (reorders) to retailers are highly dependent upon the incidence of illness within the population. Retail consumption of our products is highest during the cough and cold season, which usually runs from October through March. The Company begins extensive advertising campaigns to coincide with the cough and cold season and generally realizes higher advertising expense in the October through March timeframe. The fiscal first quarter (ending June 30th) of each year generally accounts for 7% to 8% of annual sales and, historically, we have incurred a loss in that quarter. Further, the Company records the expense for annual bonus awards when goal attainment for the bonus is reached, which is generally reflected in the fiscal fourth quarter results. Because of the seasonality of our business, results for any single quarter are not necessarily indicative of the results that may be achieved for the full fiscal year.
     Certain information is set forth below for fiscal operations (expressed in $000’s and as a percentage of net sales) on a quarterly basis for the twelve months ended March 31, for the periods indicated. The quarters indicated below have been reordered to reflect our new fiscal year, which ends March 31.
Quarterly Results:
                                                                                 
Twelve Months Ended March 31, 2008
$000s   Q1 2008   % NS   Q2 2008   % NS   Q3 2008   % NS   Q4 2008   % NS   Twelve
Months
  % NS
Net Sales
  $ 8,573       100 %   $ 28,576       100 %   $ 30,802       100 %   $ 33,022       100 %   $ 100,972       100 %
 
                                                                               
Marketing
  $ 2,143       25 %   $ 3,450       12 %   $ 16,177       53 %   $ 7,353       22 %   $ 29,123       29 %
Sales Expense
  $ 742       9 %   $ 872       3 %   $ 1,022       3 %   $ 1,202       4 %   $ 3,838       4 %
General & Administrative
  $ 2,542       30 %   $ 3,089       11 %   $ 2,400       8 %   $ 2,974       9 %   $ 11,005       11 %
Legal — Product Liability
  $ 829       10 %   $ 421       1 %   $ 444       1 %   $ 860       3 %   $ 2,554       2 %
 
Total Op Expenses
  $ 6,256       73 %   $ 7,832       27 %   $ 20,043       65 %   $ 12,389       38 %   $ 46,520       46 %
 
 
                                                                               
R&D
  $ 1,453       17 %   $ 995       3 %   $ 875       3 %   $ 785       2 %   $ 4,108       4 %
 
                                                                                 
Twelve Months Ended March 31, 2007
$000s   Q1 2007   % NS   Q2 2007   % NS   Q3 2007   % NS   Q4 2007   % NS   Twelve
Months
  % NS
Net Sales
  $ 8,206       100 %   $ 34,121       100 %   $ 36,227       100 %   $ 19,046       100 %   $ 97,601       100 %
 
                                                                               
Marketing
  $ 1,792       22 %   $ 4,136       12 %   $ 18,912       52 %   $ 5,015       26 %   $ 29,855       31 %
Sales Expense
  $ 336       4 %   $ 1,272       4 %   $ 1,126       3 %   $ 583       3 %   $ 3,317       3 %
General & Administrative
  $ 3,334       40 %   $ 2,925       9 %   $ 2,587       7 %   $ 3,729       20 %   $ 12,575       13 %
Legal — Product Liability
  $ 2,117       26 %   $ 1,576       5 %   $ 1,141       3 %   $ (597 )     (3 )%   $ 4,237       4 %
 
Total Op Expenses
  $ 7,579       92 %   $ 9,909       29 %   $ 23,766       66 %   $ 8,730       46 %   $ 49,984       51 %
 
 
                                                                               
R&D
  $ 1,863       23 %   $ 1,150       3 %   $ 545       2 %   $ 1,138       6 %   $ 4,696       5 %
 

26


Table of Contents

                                                                                 
Twelve Months Ended March 31, 2006
                                                                    Twelve    
$000s   Q1 2006   % NS   Q2 2006   % NS   Q3 2006   % NS   Q4 2006   % NS   Months   % NS
Net Sales
  $ 6,255       100    $ 25,203       100    $ 44,022       100    $ 17,676       100    $ 93,155       100 
 
                                                                             
Marketing
  $ 1,668       27 %   $ 1,981       8 %   $ 16,284       37 %   $ 6,699       38 %   $ 26,632       29 %
Sales Expense
  $ 431       7 %   $ 1,233       5 %   $ 3,038       7 %   $ 568       3 %   $ 5,270       6 %
General & Administrative
  $ 1,834       29 %   $ 2,277       9 %   $ 4,899       11 %   $ 2,302       13 %   $ 11,312       12 %
Legal — Product Liability
  $ 596       10 %   $ 1,517       6 %   $ 9,615       22 %   $ 1,123       6 %   $ 12,851       14 %
 
Total Op Expenses
  $ 4,529       73 %   $ 7,008       28 %   $ 33,836       77 %   $ 10,692       61 %   $ 56,065       60 %
 
 
                                                                               
R&D
  $ 966       15 %   $ 784       3 %   $ 1,820       4 %   $ 1,127       6 %   $ 4,697       5 %
 
Legal expense in Q3 2006 reflects recognition of approximately $8.5 million as expense related to settling the Arizona litigation and recording a reserve for the remaining lawsuits ($12.0 million settlement plus $1.3 million for litigation reserves, less $4.8 million of insurance reimbursement).
Critical Accounting Policies and Estimates
     Our consolidated financial statements and accompanying notes have been prepared in accordance with Genarally Accepted Accounting Principles (“GAAP”) applied on a consistent basis. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.
     We regularly evaluate the accounting policies and estimates that we use to prepare our consolidated financial statements. In general, management’s estimates are based on historical experience, information from third party professionals, and various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.
     We believe that our critical accounting policies and estimates include the accounting for intangible assets and goodwill, accounting for income taxes, revenue recognition, accounting for sales returns and allowances, accounting for sales discounts and promotional programs, and accounting for legal contingencies.
     Intangible Assets and Goodwill: We recorded approximately $15.0 million in goodwill in connection with the 40% Zicam, LLC interest acquired from Zensano, Inc. in December 2001. Under SFAS No. 142, goodwill must be tested when a triggering event occurs or at least annually to identify a potential impairment and the amount of any impairment loss. Factors that could affect this analysis would be significant loss of market share, a general decline in Zicam product sales, higher than expected increases in expenses and various other matters. Any change in key assumptions about the business or prospects of Zicam, LLC, or any change in market conditions or other externalities affecting Zicam, LLC, could result in an impairment charge, and such a charge could have a material adverse effect on our financial condition and results of operations. Our annual valuation of goodwill was completed in September 2007, and no impairment was identified. No triggering events have occurred subsequent to the valuation performed in the third quarter of calendar 2007.
     Income Taxes: In accordance with SFAS No. 109, “Accounting for Income Taxes,” we record income tax expense based on our estimated effective income tax rate for the year and will continue to do so in future periods. In fiscal 2006 and the three months ended March 31, 2007, we recognized a tax benefit related to the charitable donation of products. In fiscal 2008, we fully utilized the tax loss carryforward from prior years. See Note 5 to the Consolidated Financial Statements for further information regarding income taxes.

27


Table of Contents

     Revenue Recognition: The Company recognizes revenue from product sales when earned, that is, when the risks and rewards of ownership have transferred to the customer, which is considered to have occurred upon shipment of the finished product. Sales incentives, promotional allowances, and returns are estimated and recognized at the date of shipment based upon historical activity and current agreements with customers. The Company evaluates these estimates on a monthly basis and revises them as necessary.
     Customer Sales Returns and Allowances: The estimate for product returns reflects our historical experience of sales to retailers and is reviewed regularly to ensure that it reflects potential product returns. Prior to July 2006, we recorded a returns provision of 3% for products in distribution longer than one year and 7% for new items. We regularly review the similarities and differences of the new products relative to products for which we now have several years of product return experience. In July 2006, we adjusted our returns provision to 3.5% of gross sales for all of our products, including the new items that began shipping in the third quarter of 2006. Additionally, during calendar 2006, we recorded a $2.5 million adjustment to our returns provision to account for increased returns of Nasal Comfort and discontinued products from a large customer. During the fiscal year ended March 31, 2008, we experienced product returns associated with discontinued items and we recorded a $3.1 million adjustment to our returns provision, in excess of our customary 3.5% of gross sales, to account for the increased returns of discontinued products (which included several of our cough and flu products). We will continue to review the return provision at least quarterly and adjust the reserve amounts as actual product return experience continues to develop. Additionally, when a determination is made that a product will be discontinued, we will adjust the returns provision. Should the actual level of product returns vary significantly from our estimates, our operating and financial results would be materially affected.
     Accounts Receivable and Allowance for Doubtful Accounts: The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The allowance is reviewed regularly to ensure that it reflects the amount of the Company’s probable credit losses. During the quarter ended June 30, 2007, the Company reviewed the allowance and based on historical performance elected to reduce its accrual rate from 0.10% of gross sales to 0.02% of gross sales, effective April 1, 2007. In addition, during the quarter ended June 30, 2007, the Company reduced its allowance by approximately $250,000, which was reflected in general and administrative expense in the accompanying statement of income for the year ended March 31, 2008.
     Insurance Reimbursements: During the fiscal year ended March 31, 2008, we recorded approximately $560,000 in expected reimbursement from our insurance carriers. The reimbursement relates to product liability litigation defense costs. We believe the amounts are reasonable based on the terms of the respective policies and the costs incurred to date. We do not expect any additional reimbursements from our insurance carriers for legal expenses incurred in fiscal 2009 or any future periods to be sizable. See Part I, Item 3 —“Legal Proceedings” for additional information regarding our insurance program.
     Legal Contingencies: We are subject to lawsuits, investigations and claims arising out of the normal conduct of our business. See Part I, Item 3 —“Legal Proceedings” for information regarding our pending and threatened litigation and our reserves for product liability litigation. While we are vigorously defending ourself in these proceedings, the outcome of these and any other proceedings that may arise cannot be predicted with certainty. The Company follows the guidance of SFAS 5, “Accounting for Contingencies,” which states that the Company is required to accrue a contingent loss when the loss is deemed probable and reasonably estimable.

28


Table of Contents

Results Of Operations For The Year Ended March 31, 2008 Compared To The Twelve Months Ended March 31, 2007
     Certain information is set forth below for our operations expressed in $000’s and as a percentage of net sales for the periods indicated:
                                 
    Year Ended March 31,  
    2008     2007  
Net sales
  $ 100,972       100 %   $ 97,601       100 %
Cost of sales
    34,532       34       33,628       34  
 
                       
Gross profit
    66,440       66       63,973       66  
Selling, general and administrative
    46,520       46       49,984       51  
Research & development
    4,108       4       4,696       5  
 
                       
Income from operations
    15,812       16       9,293       10  
Interest and other income
    653             531        
Interest expense
                (117 )      
 
                       
Income before income taxes
    16,465       16       9,707       10  
Provision for income taxes
    6,037       6       3,168       3  
 
                       
Net income
  $ 10,428       10 %   $ 6,539       7 %
 
                       
Net Sales
     Net sales for fiscal 2008 were approximately $101.0 million, or 3% above net sales of $97.6 million for the twelve months ended March 31, 2007. We believe the increase in sales compared to the prior year is related to the introduction of our new multi-symptom products, the increased level of retail sales of our products to consumers, offset by retailers reduced inventory levels and reductions in sales of our cough products. Sales have been affected by retailers’ maintaining a lower level of inventory and more closely aligning their repurchases with retail consumption during the cold season. During the quarter ended September 30, 2007, we initiated a 3% price increase for our Cold Remedy products. This is the first price increase since Zicam products were introduced in 1999. Our new multi-symptom products (which began shipping during the second fiscal quarter) have a selling price that is below the selling price of all of our other products. We are evaluating our current pricing structure and anticipate raising prices on certain of our products during fiscal 2009. The average net selling price per unit, for the year ended March 31, 2008, was comparable to the average net selling price per unit in the twelve months ended March 31, 2007.
Cost of Sales
     For the year ended March 31, 2008, our cost of sales increased approximately $900,000 to approximately $34.5 million, compared to the cost of sales for the year ended March 31, 2007 of approximately $33.6 million. The increase was due to the higher number of units sold. Our cost of goods sold varies by product and is affected by the mix of products sold.
Gross Profit
     Gross profit for the year ended March 31, 2008 was approximately $66.4 million, compared to gross profit of approximately $64.0 million for year ended March 31, 2007. The increased gross profit is due to the higher level of sales during the period (compared to the prior year). Gross margins for fiscal 2008 were 66%, equivalent to the 66% gross margins recorded for the twelve months ended March 31, 2007. The price increase on Cold Remedy products, initiated in the quarter ended September 30, 2007, was somewhat offset by the lower average net sales price per unit for the new multi-symptom products, which began shipping during the three months ended September 30, 2007. In addition, gross margin was negatively impacted by approximately $3.1 million in product returns, in excess of our customary returns allowance, associated with discontinued products. The recording of an additional $1.1 million to the inventory reserve to account for expiring products and obsolete components also negatively impacted gross margin. Gross margins on our existing products vary between 55% and 80%. Gross margin will continue to be affected by the relative mix of products sold and changes in product sales price and costs.

29


Table of Contents

Selling, General & Administrative (SG&A)
     SG&A expense for 2008 decreased to $46.5 million from approximately $50.0 million in the twelve months ended March 31, 2007. Litigation expense related to the product liability lawsuits was approximately $2.5 million (net of approximately $560,000 for insurance reimbursements), compared to approximately $4.2 million in the twelve months ended March 31, 2007 (net of $1.6 million for insurance reimbursements). We anticipate legal defense costs will be $500,000 to $750,000 per quarter during fiscal 2009.
     The lower SG&A expense in the year ended March 31, 2008 compared to 2007, is primarily due to the lower product liability litigation expense as well as a decrease of approximately $1.1 million in general legal expenses that were primarily associated with the Federal Trade Commission (FTC) inquiry initiated in early 2006, which has since been closed with no adverse findings. Additionally, there was approximately $1.3 million of additional expense incurred in the twelve months ended March 31, 2007 associated with a charitable donation of short-dated products. Charitable donations of products during fiscal 2008 were approximately $100,000. Also, during fiscal 2008, we determined that our allowance for bad debt exceeded the amount of loss that would likely be incurred and we reduced the allowance amount by approximately $250,000, which reduced SG&A expenses by an equal amount.
     Lower SG&A expense was also due to a $730,000 decrease in marketing expenses, primarily related to significant decreases in marketing expense associated with Nasal Comfort, offset by increased marketing associated with the Xcid antacid introduction. Due to the change in the Company’s fiscal year, we believe advertising expenses can be better managed across the entire cold season to increase consumer awareness of our products and we expect to spread our advertising across the entire cold season during fiscal 2009. Offsetting those SG&A decreases was a $520,000 increase in sales expense associated with hiring and training our new trade sales force to call on national and regional retail accounts, wholesale distribution companies, and to oversee brokers. In addition, labor expense increased approximately $340,000 due to increased headcount.
     We expect SG&A expenses in future periods will vary largely in relation to the level of our advertising and legal expenditures. Advertising expense is heaviest during the cold season, which occurs October through March. We anticipate that we will continue to incur approximately $500,000 to $750,000 in legal expense each quarter as a result of the Zicam Cold Remedy product liability litigation matters in which we are engaged (see Part 1, Item 3 — “Legal Proceedings”).
Research and Development
     Research and development expense was approximately $4.1 million in fiscal 2008, approximately $600,000 less than the level incurred in the twelve months ended March 31, 2007. The research and development spending reflects scale-up costs related to new products, including our new multi-symptom and antacid products, and our goal of continuing to expand the business by developing products in the oral care, cold sore, and other categories. The timing of research and development spending can vary throughout the year and is not generally associated with our seasonal sales patterns. We expect to invest approximately 3% to 4% of fiscal 2009 annual net sales in research and development efforts.
Interest & Other Income
     Interest and other income was approximately $653,000 in the year ended March 31, 2008, versus approximately $531,000 in the comparable twelve months of the prior year. The increase in interest income is associated with our increased cash balances offset by lower interest rates. For the year ended March 31, 2007, interest income of $531,000 was offset by interest expense of $117,000 related to borrowings outstanding under our credit facility. There was no interest expense in fiscal 2008. Interest income in future periods will vary based on our level of cash and interest rate levels.
Income Before Income Taxes
     Income before income tax for fiscal 2008 was approximately $16.5 million, compared to approximately $9.7 million for the year ended March 31, 2007. The increased income level is due to the higher net sales achieved and lower SG&A expenses during the year ended March 31, 2008. We expect that income in future periods will be significantly impacted by the sales levels of our products including: new Zicam products to be introduced in fiscal

30


Table of Contents

2009; product introductions in new categories, and annual changes in our advertising; research and development; and legal expenses. We anticipate quarterly earnings will continue to vary along with the seasonality of sales.
Provision for Income Tax Expense
     We recorded income tax expense at our combined estimated annual effective tax rate of approximately 39% and adjusted for the tax effects of certain transactions including research and development tax credits and charitable donations . We recognized income tax expense of approximately $6.0 million during fiscal 2008, versus approximately $3.2 million for the twelve months ended March 31, 2007. The lower effective tax rate in the year ended March 31, 2007 period was associated with the charitable donation of products.
Net Income
     Net income was approximately $10.4 million in fiscal 2008, compared to $6.5 million for the year ended March 31, 2007.
Results Of Operations For The Three Months Ended March 31, 2007 Compared To The Three Months Ended March 31, 2006
     Certain information is set forth below for our operations expressed in $000’s and as a percentage of net sales for the periods indicated:
                                 
    Three Months Ended March 31,  
    2007     2006  
Net sales
  $ 19,046       100 %   $ 17,676       100 %
Cost of sales
    7,048       37       5,865       33  
 
                       
Gross profit
    11,998       63       11,811       67  
Selling, general and administrative
    8,730       46       10,693       60  
Research & development
    1,138       6       1,127       6  
 
                       
Income (Loss) from operations
    2,130       11       (9 )      
Interest and other income
    203       1       174       1  
Interest expense
                       
 
                       
Income before income taxes
    2,333       12       165       1  
Provision for income taxes
    624       3       68        
 
                       
Net income
  $ 1,709       9 %   $ 97       1 %
 
                       
Net Sales
     Net sales for the three months ended March 31, 2007 increased to approximately $19.0 million or 8% above net sales of $17.7 million for the three months ended March 31, 2006. The increase was principally due to an increase in the number of units sold. We did not change the list price for our products during the quarter. The increase in net sales was attributable to unit sales growth of our allergy/sinus and multi-symptom relief products.
Cost of Sales
     The cost of sales for the three months ended March 31, 2007 increased approximately $1.2 million or 20% over the cost of sales during the comparable period in 2006. The increase was due to the higher number of units sold, as well as the recording of approximately $800,000 to account for expiring products and obsolete components, of which $500,000 was in excess of our customary amount. We recorded approximately $150,000 for the disposal of tooling associated with our flu products’ prior design.
Gross Profit
     Gross profit for the three-month transition period ended March 31, 2007 increased to approximately $12.0 million or 2% above gross profit in the comparable period in the prior year. The increased gross profit was due to the increased sales, partially offset by the higher cost of goods sold. The gross margin percentage achieved during the three-month transition period ended March 31, 2007 decreased to 63% compared to the gross margin achieved in

31


Table of Contents

the comparable period in the prior year of 67%. The gross margin percentage on product offerings varied between 50% and 80%; therefore, average gross margin is affected by the relative mix of products sold and any adjustments to account for expiring product.
Selling, General and Administrative Expenses
     Selling, general and administrative expense for the three months ended March 31, 2007 decreased to approximately $8.7 million from $10.7 million in the comparable period the prior year. The decrease in operating expense was principally due to recognition of approximately $1.6 million in insurance reimbursements related to product liability litigation defense costs incurred prior to 2006 and a decrease in marketing expense compared to the three months ended March 31, 2006. During the three months ended March 31, 2007, we recorded approximately $1.0 million for product liability defense costs, offset by $1.6 million in insurance reimbursements, which resulted in net litigation defense costs of approximately ($0.6) million compared to litigation defense costs of $1.1 million for the three months ended March 31, 2006.
     During the three months ended March 31, 2007, marketing and advertising expense decreased $1.7 million (approximately $5.0 million in 2007 compared to $6.7 million in 2006) due to a lower level of television advertising compared to the prior year. Expenses for the three months ended March 31, 2007 were also affected by $750,000 associated with the charitable donation of short-dated Zicam products. Additionally, labor expense increased approximately $350,000 for the three months ended March 31, 2007, compared to the comparable period in 2006.
Research & Development
     Research and development expense for the three months ended March 31, 2007 was $1.1 million which was approximately equal to the level realized for the three months ended March 31, 2006. Our research and development expenses were related to developing new Zicam products to be introduced in fiscal 2008 and continuing development work on our oral care and antacid products.
Interest & Other Income
     Interest income was $200,000 for the three months ended March 31, 2007, an immaterial increase from the three months ended March 31, 2006.
Income Before Income Taxes
     Income before income tax for the three months ended March 31, 2007 increased to approximately $2.3 million from $165,000 in the prior year. The increase was related to the lower selling, general and administrative expenses discussed above.
Provision for Income Tax Expense
     For the three months ended March 31, 2007, we recorded a provision for income tax expense at our combined federal and state estimated effective tax rates of 39%. We also recognized tax credits related to the $750,000 charitable donation of Zicam products in the three months ended March 31, 2007.
Net Income
     Net income increased approximately $1.6 million to approximately $1.7 million for the three months ended March 31, 2007, compared to net income for the three months ended March 31, 2006 of approximately $97,000. The increase reflects the higher operating income and tax benefits related to the donated products.

32


Table of Contents

Results Of Operations For The Year Ended December 31, 2006 Compared To The Year Ended December 31, 2005
     Certain information is set forth below for our operations expressed in $000’s and as a percentage of net sales for the periods indicated:
                                 
    Years Ended December 31,  
    2006     2005  
Net sales
  $ 96,230       100 %   $ 90,460       100 %
Cost of sales
    32,445       34       28,201       31  
 
                       
Gross profit
    63,785       66       62,259       69  
Selling, general and administrative
    51,946       54       54,196       60  
Research & development
    4,685       5       4,069       5  
 
                       
Income from operations
    7,154       7       3,994       4  
Interest and other income
    502       1       417        
Interest expense
    117                    
 
                       
Income before income taxes
    7,539       8       4,411       4  
Provision for income taxes
    2,612       3       1,333       1  
 
                       
Net income
  $ 4,927       5 %   $ 3,078       3 %
 
                       
Net Sales
     Net sales for 2006 increased to approximately $96.2 million or 6% above net sales of $90.5 million in 2005. The increase was principally due to an increase in the number of units sold. We did not change the list price for our products during 2006. The increase in net sales is attributable to unit sales growth of Cold Remedy products, primarily oral delivery. We believe the increase in net sales was less than expected due to the slow start to the cold season in the fourth quarter of 2006. Sales of our cough and multi-symptom cold/flu relief products declined in 2006. We experienced a large amount of Nasal Comfort returns in 2006 resulting in returns exceeding net sales for these products.
Cost of Sales
     The cost of sales for 2006 increased approximately $4.2 million or 15% over the cost of sales in 2005. The increase is due to the higher number of units sold, as well as a higher average unit cost in 2006. The cost per unit sold in 2006 increased approximately 6% compared to the cost per unit sold in 2005. Cost of goods sold was negatively affected by new products, and higher costs associated with increased promotional displays.
Gross Profit
     Gross profit in 2006 increased to approximately $63.8 million or $1.5 million above gross profit in 2005. The increased gross profit is due to the increased sales, partially offset by the higher cost per unit sold. The gross margin percentage achieved in 2006 decreased to 66% compared to the gross margin achieved in 2005 of 69%. The gross margin percentage for our products varied between 50% and 80%; therefore, our average gross margin was affected by the relative mix of products sold. Our average gross margin percentage was below our goal of 70% primarily due to start-up costs for new items, a $2.5 million adjustment to our returns provision to account for increased returns of Nasal Comfort and discontinued products, and increased costs for promotional displays.
Selling, General and Administrative Expenses
     Selling, general and administrative expense for 2006 decreased to approximately $51.9 million from $54.2 million in 2005, principally due to a decrease in product liability expense. In 2005, we recorded charges of $12 million to settle the Arizona litigation (less $4.8 million in expected insurance reimbursement) and $1.3 million to establish a reserve for the remaining litigation. This net decrease in cost of $8.5 million from 2005 was partially offset in 2006 by an increase in defense costs from $4.2 million in 2005 ($6.2 million less $2.0 million in expected

33


Table of Contents

insurance recoveries ) to $6.0 million in 2006. Legal costs in 2006 were also impacted by the cost of responding to the inquiry by the FTC.
     During 2006, marketing and advertising expense increased $6.5 million (approximately $31.5 million in 2006 compared to $25.0 million in 2005). Advertising expense increased approximately $5.5 million to $25.3 million in 2006 from $19.8 million in 2005. Non-advertising marketing expense increased $1.0 million, primarily related to consumer research, public relations, and sampling programs.
     Sales expense decreased $2.0 million during 2006 because bonus amounts for achieving sales goals were not earned. Similarly, labor expense decreased $1.7 million due to the failure to achieve goals related to the payment of officer and management bonuses.
     Expenses were also impacted by a $600,000 cost associated with the charitable donation of cough products in 2006.
Research & Development
     Research and development expense increased from approximately $4.1 million in 2005 to approximately $4.7 million in 2006. Our research and development expenses were related to developing new Zicam products introduced in 2006 and continuing development work on our oral care and antacid products.
Interest & Other Income
     Other income increased to $0.5 million in 2006, approximately $80,000 higher than 2005 due to higher interest income.
Interest Expense
     In July 2006, we borrowed $4 million against our credit facility with Comerica Bank to fund seasonal working capital needs, resulting in approximately $116,000 in interest expense. We repaid the borrowing in the fourth quarter of 2006 and ended the year with no debt outstanding. We did not incur any interest expense during 2005.
Income Before Income Taxes
     Income before income tax for 2006 increased to approximately $7.5 million from $4.4 million in 2005. The increase is related to the increase in sales and gross profit. Additionally, in 2005 there was an $8.5 million charge related to the settlement of litigation (net of insurance reimbursement) and the establishment of a reserve for remaining lawsuits. We expect that income in future periods will be significantly impacted by the success of our current products, new product introductions, and year-over-year changes in our advertising, research and development, and legal expenses.
Provision for Income Tax Expense
     In 2006, we recorded a provision for income tax expense at our combined federal and state estimated effective tax rates of 39%. We also recognized tax credits related to the charitable donation of cough product and investment in research and development.
Net Income
     Net income increased approximately $1.8 million, or 60%, to approximately $4.9 million in 2006, compared to net income for 2005 of approximately $3.1 million. The increase reflects the higher sales and gross margin dollars in 2006. Net income in 2005 was adversely affected by litigation settlements and reserves (see Part I, Item 3 — “Legal Proceedings”).

34


Table of Contents

Liquidity and Capital Resources
     Our working capital was $44.6 million as of March 31, 2008, compared to $38.7 million at March 31, 2007. During fiscal 2008, we experienced an increase in available cash of approximately $11.0 million. The increase is primarily due to increased sales in 2008 having been converted to cash and reduced selling, general and administrative expenses. In addition, the Company repurchased 516,401 shares of our common stock for approximately $7.5 million in fiscal 2008.
     During the fiscal year ended March 31, 2008, trade receivables increased to $12.1 million from $8.3 million on March 31, 2007, primarily due to the late cold season. We have converted substantially all of those receivables to cash during our first fiscal quarter of 2009. The Company’s principal source of liquidity is cash generated from sales of our products to retailers and distributors. The majority of sales are given 30 day credit terms; however, payment terms are occasionally extended, as retailers begin to increase inventory of our products prior to the onset of the cough and cold season. The Company records an estimated allowance for potentially uncollectible accounts, which is reviewed on a monthly basis. During our review of the quarter ended June 30, 2007, we determined that our allowance for bad debt exceeded the amount of loss that would likely be incurred and we reduced the allowance amount by approximately $250,000. This reduction was reflected in selling, general and administrative expenses during that quarter. We believe our allowance as of March 31, 2008 is adequate.
     Generally, to the extent our operations are profitable, our business is cash flow positive. The change in accounts receivable, inventory, accounts payable and accrued expenses largely reflects the increase in the Company’s business and reflects the seasonal nature of the Company’s business. Our working capital requirements fluctuate with the seasonality of our sales and are generally highest in the July through September quarter. The Company records the bulk of its sales, which is reflected in higher accounts receivable, in the second, third, and fourth fiscal quarters; generally builds inventory during the first through third fiscal quarter periods; and advertises its products, which is the largest component of accrued expenses, primarily in the third and fourth fiscal quarters. Although affected by the build-up of inventory, accounts payable and accrued expenses are more significantly affected by advertising spending, which occurs primarily in the third and fourth fiscal quarters.
     Historically, the Company has had very low capital expenditures since we rely on contract manufacturers to produce our products. Typical capital expenditures include investments in technology, office furniture, leasehold improvements, and small tooling requirements. However, during calendar 2006 the Company spent approximately $4.2 million for an automated manufacturing line that is presently producing our swab products. The Company occasionally provides deposits and prepayments to our manufacturers to improve and increase manufacturing capabilities for our products. Additionally, the Company’s facility lease for its corporate offices expired during fiscal 2008 and we leased new corporate office and R&D space in March, 2008. The relocation required capital expenditures and tenant improvements of approximately $650,000, which we will amortize over the term of the new lease (approximately five years) including expected renewal periods or the estimated useful life, whichever is shorter.
     We have an $8.0 million credit facility with Comerica Bank that was renewed in July 2007, until July 2009. The interest rate under the renewed credit facility is prime minus 0.25% (or 5.0% at March 31, 2008). In July 2006, we borrowed $4 million under the facility to support our working capital requirements in the third calendar quarter of 2006. We repaid the debt in the quarter ended December 31, 2006. We do not anticipate any borrowings from the credit facility for working capital needs during the next quarter. We are in compliance with the earnings and financial covenants contained in the credit facility. We believe that our existing capital resources and our credit line will be sufficient to fund our operations and capital requirements for the next 12 months.

35


Table of Contents

Contractual Obligations
     We have entered into certain long-term contractual obligations that will require various payments over future periods as follows:
                                         
    Contractual Cash Obligations  
    (In thousands of dollars)  
    Payments due by Period as of March 31, 2008  
            Less than                     After  
    Total     1 year     1-3 years     3-5 years     5 years  
Long-Term Debt Obligations
  $ 0     $ 0     $ 0     $ 0     $ 0  
Capital Lease Obligations
    0       0       0       0       0  
Operating Lease Obligations
    2,570       416       1,061       977       116  
Purchase Obligations
    1,214       1,214       0       0       0  
Other Long-Term Liabilities Reflected on the Company’s Balance Sheet under GAAP
    0       0       0       0       0  
 
                             
Total
  $ 3,784     $ 1,630     $ 1,061     $ 977     $ 116  
 
                             
Recently Issued Accounting Standards
     See Note 1 for a discussion of stock-based compensation accounting standards that became effective January 1, 2006.
     In July 2006, the Financial Accounting Standards Board (“FASB”) issued Interpretation No. 48, “Accounting for Uncertainty in Income Taxes” (FIN 48), effective for fiscal years beginning after December 15, 2006. The interpretation applies to tax positions within the scope of SFAS No. 109, Accounting for Income Taxes. FIN 48 is a two-step process for recognition and evaluation of uncertain tax positions. It requires the Company to assess whether a tax position is “more-likely-than-not” to be sustained based on its technical merits and then to determine the amount of the tax position to be recognized in the financial statements. The Company implemented FIN 48 beginning January 1, 2007. Adoption of FIN 48 did not have a material impact on our earnings, financial position, or cash flows. As of March 31, 2008, the Company believes that all of its tax positions are more likely than not to be sustained based on their technical merits.
     In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements” (SFAS 157), effective for fiscal years beginning after November 15, 2007. SFAS 157 provides guidance on how to measure assets and liabilities that use fair value, and expands disclosure about fair value measurement. SFAS 157 will apply whenever another GAAP standard requires (or permits) assets or liabilities to be measured at fair value but does not expand the use of fair value to any new circumstances. The Company adopted SFAS 157 as of April 1, 2008. Adoption of SFAS 157 is not expected to have a material impact on our earnings, financial position, or cash flows.
     In September 2006, the U.S. Securities and Exchange Commission issued Staff Accounting Bulletin No. 108 (SAB 108), “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements.” SAB 108 provides guidance on the consideration of the effects of prior year misstatements in quantifying current year misstatements in determining whether the current year’s financial statements are materially misstated. SAB 108 is effective for fiscal years ending after November 15, 2006. The Company has adopted SAB 108 as of December 31, 2006, and its adoption did not have an impact on the Company’s consolidated financial statements.
     In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities: Including an amendment of FASB Statement No. 115” (SFAS 159). SFAS 159 permits entities to measure many financial instruments and certain other items at fair value with changes in fair value reported in earnings. The FASB issued SFAS 159 to mitigate earnings volatility that arises when financial assets and liabilities are measured differently, and to expand the use of fair value measurement for financial instruments. SFAS 159 is effective as of the beginning of the first fiscal year that begins after November 15, 2007. We adopted SFAS 159 beginning April 1, 2008. Adoption of SFAS 159 is not expected to have a material impact on our earnings, financial position, or cash flows.
     In December 2007, the FASB issued SFAS No. 141R, “Business Combinations Statement 141R,” a replacement of FASB No. 141. SFAS 141R is effective for fiscal years beginning on or after December 15, 2008 and applies to

36


Table of Contents

all business combinations. SFAS 141R provides that, upon initially obtaining control, an acquirer shall recognize 100% of the fair value of acquired assets, including goodwill, and assumed liabilities, with only limited exceptions, even if the acquirer has not acquired 100% of its target. Additionally, SFAS 141R changes current practice, in part, as follows: (1) contingent consideration arrangements will be fairly valued at the acquisition date and included on that basis in the purchase price consideration; (2) transaction costs will be expensed as incurred, rather than capitalized as part of the purchase price; (3) pre-acquisition contingencies, such as legal issues, will generally have to be accounted for in purchase accounting at fair value; and (4) in order to accrue for a restructuring plan in purchase accounting, the requirements in FASB No. 146, "Accounting for Costs Associated with Exit or Disposal Activities,” would have to be met at the acquisition date. While there is no expected impact to our consolidated financial statements on the accounting for acquisitions completed prior to April 1, 2009, the adoption of SFAS 141R on April 1, 2009 could materially change the accounting for business combinations consummated subsequent to that date.
          In March 2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities — an amendment of FASB Statement No. 133” (“SFAS 161”), which modifies and expands the disclosure requirements for derivative instruments and hedging activities. SFAS 161 requires that objectives for using derivative instruments be disclosed in terms of underlying risk and accounting designation and requires quantitative disclosures about fair value amounts and gains and losses on derivative instruments. It also requires disclosures about credit-related contingent features in derivative agreements. SFAS 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application encouraged. SFAS 161 encourages, but does not require, comparative disclosures for earlier periods at initial adoption. The adoption of SFAS 161 is not expected to have a material impact on our consolidated financial condition or results of operations.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTORS
Forward Looking Statements
          This Report on Form 10-K, including documents incorporated herein by reference, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “estimate,” “anticipate,” “intend,” “may,” “might,” “will,” “would,” “could,” “project” and “predict,” or similar words and phrases generally identify forward-looking statements. Forward looking statements contained herein and in documents incorporated by reference herein include, but are not limited to statements regarding:
    Our belief that the reserve for litigation losses will be sufficient to resolve the remaining cases;
 
    our expectations regarding a net loss for the first quarter of fiscal 2009;
 
    our expectation of introducing new products during the 2008/2009 cold season;
 
    our expectation regarding continued expansion of the Zicam line of products;
 
    our belief that growth in sales of our products will occur;
 
    our belief that our claims and advertising comply in all material respects with regulatory requirements;
 
    our belief that advertising approaches and public relations efforts will continue to build brand awareness;
 
    our anticipation that we will continue to incur approximately $500,000 to $750,000 in legal expense each quarter as a result of the Zicam Cold Remedy product liability and securities litigation in which we are engaged;
 
    our intention to vigorously defend the Zicam Cold Remedy product liability and securities litigation claims, our expectation that additional product liability lawsuits may be filed against us, and our belief that any

37


Table of Contents

      liability resulting from these or other lawsuits, including any adverse publicity, could materially impact our financial results;
    our expectation that we will continue to file for patent and trademark protection for products that we develop and introduce in the future;
 
    our expectation that the trend of growth in sales in future periods will continue as we expand consumer awareness and acceptance of our entire Zicam brand of products, increase distribution, introduce new products, and avoid additional adverse publicity;
 
    our expectation regarding future net income, our belief that expenditures for advertising and research and development will vary by quarter throughout the year, and our expectation that advertising expenses will be heaviest in our third and fourth fiscal quarters;
 
    our expectations regarding environmental matters;
 
    our expectation that our mix of products sold will change due to seasonality and varying growth rates within our four market categories;
 
    our expectation of our 10 largest retailers adding new products;
 
    our anticipation of sales price increases in fiscal 2009;
 
    our expectations regarding retailer inventory management;
 
    our expectation of continuing profitability in future years;
 
    our intention to review our product return reserve provision monthly and adjust the reserve amounts as actual product return experience continues to develop;
 
    our expectation of making income tax payments at our statutory rates in future years;
 
    our expectation that the average unit cost of goods sold and gross margin will continue to be affected by the relative mix of products sold;
 
    our expectation that our net income and operating expenses in future periods will vary largely in connection with the level of our sales, advertising, research and development, and legal expenses;
 
    our expectation that research and development spending will be 3% to 4% of annual net sales in subsequent years;
 
    our expectation regarding dividends and retained earnings;
 
    our expectation regarding investments in equipment;
 
    our expectations regarding derivative instruments;
 
    our expectation that earnings in future periods will be significantly impacted by the seasonality of our sales, the severity of the cold season, the revenues and expenses associated with new products, and the timing and amount of advertising, research and development, and legal expenses;
 
    our belief that our existing capital resources and our credit line will be sufficient to fund our operations and capital requirements for the next 12 months;
 
    our expectation regarding reimbursement for legal expense from our insurance carriers;

38


Table of Contents

    our having no plans to directly manufacture and store our products;
 
    our expectation of introducing products in the Canadian market through a Canadian distributor in fiscal 2009;
 
    our expectation that our manufacturers will be able to timely produce inventory adequate for sales of products through the 2008/2009 cough and cold season;
 
    our expectation of achieving a higher gross margin in the future; and
 
    our belief that moderate interest rate increases will not have a material adverse impact on our results of operations or financial position in the foreseeable future.
          We may make additional written or oral forward-looking statements from time to time in filings with the Securities and Exchange Commission or in public news releases. Such additional statements may include, but not be limited to, projections of revenues, income or loss, capital expenditures, acquisitions, plans for future operations, financing needs or plans, the impact of inflation and plans relating to our products or services, as well as assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying our forward-looking statements.
          Statements in this Report on Form 10-K, including those set forth in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” describe factors that could contribute to or cause actual results to differ materially from our expectations. Other such factors include (i) less than anticipated demand for our current and future products, (ii) a weak cough and cold season, (iii) lack of market acceptance for or uncertainties concerning the efficacy or safety of our current and future products or regulatory actions, including product recalls, involving our products, (iv) difficulties in increasing production or maintaining sufficient inventories to meet unexpectedly high demand in the short term, (v) financial difficulties encountered by one or more of our principal customers, (vi) difficulties in obtaining additional capital for marketing, research and development, and other expenses, (vii) material litigation involving patent and contractual claims, product liability claims, consumer issues and securities violation claims, (viii) the possibility of delays or other difficulties in implementing product improvements and introducing to the marketplace new products and brands, (ix) unanticipated issues with suppliers, (x) the possibility that future sales of our products will not be as strong as expected, and (xi) adverse publicity regarding our products or advertising restrictions.
          Forward-looking statements contained in this Report on Form 10-K speak only as of the date of this Report on Form 10-K or, in the case of any document incorporated by reference, the date of that document. We do not undertake, and we specifically disclaim any obligation, to publicly update or revise any forward-looking statement contained in this Report on Form 10-K or in any document incorporated herein by reference to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
          Our primary market risk exposure relates to our variable rate revolving line of credit with Comerica Bank. In July 2006, we borrowed $4 million against our credit facility with Comerica Bank. The primary purpose for the borrowing was to provide additional liquidity as we built inventory for expected increases in sales during the second half of 2006. We generally extend payment terms for customers during the third calendar quarter as customers purchase new products and build inventory for the upcoming cough and cold season. We repaid the debt in the fourth calendar quarter of 2006 and ended fiscal 2006 with no debt. We did not have any borrowings during the transition quarter ended March 31, 2007 or the fiscal year ended March 31, 2008. Consequently, we believe that moderate interest rate increases will not have a material adverse impact on our results of operations or financial position in the foreseeable future.
          As of March 31, 2008, we did not participate in any market risk-sensitive commodity instruments for which fair value disclosure would be required under Statement of Financial Accounting Standards No. 107. We believe that we are not subject in any material way to other forms of market risk, such as foreign currency exchange risk or foreign customer purchases (of which there were none in the year ended March 31, 2008) or commodity price risk.

39


Table of Contents

     As we continue to develop plans to initiate international sales, beginning in Canada in 2009, we will evaluate whether will be subject to currency exchange risk in any material way. We do not anticipate using derivative financial instruments to manage foreign currency risk. If the volume of international business grows, we will assess the potential effects that changes in foreign currency exchange rates could have on our business. If we believe this potential impact presents a significant risk to our business, we may enter into additional derivative financial instruments to mitigate this risk.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
     The Report of Independent Registered Public Accounting Firm and Consolidated Financial Statements of Matrixx, including the Notes to those statements, are included in Part IV, Item 15 of this Annual Report on Form 10-K.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
     a) Evaluation of Disclosure Controls and Procedures
We carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15 and 15d-15 of the Securities Exchange Act of 1934 as of the end of the period covered by this report. Based on such evaluation, such officers have concluded that our disclosure controls and procedures were effective as of March 31, 2008 in alerting them on a timely basis to material information relating to us (including our consolidated subsidiaries) required to be included in our filings under the Exchange Act.
     b) Management’s Annual Report on Internal Control Over Financial Reporting
     Management of the Company, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting as defined by rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company’s internal control over financial reporting includes those policies and procedures that:
  (i)   pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
 
  (ii)   provide reasonable assurance that the transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with the authorizations of management and directors of the Company; and
 
  (iii)   provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect of the financial statements.
     Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that

40


Table of Contents

controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of the Company’s internal control over financial reporting as of March 31, 2008. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework.
     Management’s assessment included an evaluation of the design of our internal control over financial reporting and testing the operational effectiveness of our internal control over financial reporting.  Management reviewed the results of the assessment with the Audit Committee of the Board of Directors.  Based on such assessment, management determined that, at March 31, 2008, we maintained effective internal control over financial reporting.
     Mayer Hoffman McCann, P.C., the independent registered public accounting firm that audited the consolidated financial statements of the Company included in this Annual Report on Form 10-K, has issued a report on management’s assessment of the effectiveness of the Company’s internal control over financial reporting as of March 31, 2008. The report is included below in this Item under the heading “Report on Internal Control over Financial Reporting of Independent Registered Public Accounting Firm.”

41


Table of Contents

REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
Matrixx Initiatives, Inc.
     We have audited management’s assessment, included in the accompanying Management’s Annual Report on Internal Control Over Financial Reporting, that Matrixx Initiatives, Inc. and subsidiaries (the “Company”) did maintain effective internal control over financial reporting as of March 31, 2008, based on the criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an opinion on the effectiveness of the Company’s internal control over financial reporting based on our audit.
     We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
     A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
     Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
     In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of March 31, 2008, based on the criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.
     We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements as of and for the year ended March 31, 2008 of the Company and our report dated June 11, 2008 expressed an unqualified opinion on those consolidated financial statements.
/s/ Mayer Hoffman McCann, P.C.
MAYER HOFFMAN MCCANN P.C.
Phoenix, Arizona
June 12, 2008

42


Table of Contents

ITEM 9B. OTHER INFORMATION
None.
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
     The information required by this Item for our executive officers is set forth in Part I of this Form 10-K under the heading “Executive Officers of Matrixx.” Other information required by this Item is set forth in our Proxy Statement relating to our 2008 annual meeting of stockholders to be held on August 26, 2008 (the “2008 Proxy Statement”), under the headings, “Information Concerning Directors,” “Section 16(a) Beneficial Ownership Reporting Compliance,” “Additional Information — How do we submit shareholder proposals and director nominations for the next Annual Meeting?” and “Information about our Board, Its Committees and our Corporate Governance — What are the responsibilities of the Audit Committee?” and is incorporated herein by this reference as if set forth in full.
     We have adopted a Code of Ethics that applies to our principal executive officer, our principal financial officer and our controller, as well as to all of our other employees. A copy of the Code of Ethics was attached as an exhibit to our Annual Report on Form 10-K for the period ended December 31, 2003 and is available on our website (www.matrixxinc.com). We will make a copy of the Code of Ethics available to any person without charge, upon request, by writing to Matrixx Initiatives, Inc., 8515 E. Anderson Dr., Scottsdale, AZ 85255, Attn: Corporate Secretary. If we make any substantive amendment to the Code of Ethics or grant any waiver, including any implicit waiver, we will disclose the nature of such amendment or waiver in a Report on Form 8-K within four business days after such amendment is made or such waiver is given.
ITEM 11. EXECUTIVE COMPENSATION
     The information required by this Item is set forth in the 2008 Proxy Statement, under the headings, “Executive Compensation,” “Director Compensation” and “Compensation Committee Interlocks and Insider Participation” and is incorporated herein by this reference as if set forth in full.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
     The information required by this Item for certain of our beneficial owners is set forth in the 2008 Proxy Statement, under the heading, “Security Ownership of Certain Beneficial Owners and Management,” and is incorporated herein by this reference as if set forth in full.
Securities Authorized for Issuance Under Equity Compensation Plans
     The following table sets forth information as of March 31, 2008 with respect to our compensation plans and individual compensation arrangements under which our equity securities were authorized for issuance to directors, officers, employees, consultants and certain other persons and entities in exchange for the provision to us of goods or services.

43


Table of Contents

                         
                    Number of Securities
                    Remaining Available for
    Number of Securities   Weighted- Average   Future Issuance Under
    to be Issued Upon   Exercise Price of   Equity
    Exercise of   Outstanding   Compensation Plans
    Outstanding Options,   Options, Warrants,   (Excluding Securities
Plan Category   Warrants, and Rights   and Rights   Reflected in Column (a))
 
    (a)       (b)       (c)  
Equity compensation plans approved by security holders
    549,134     $ 12.27       337,707  
Equity compensation plans not approved by security holders
          N/A       N/A  
Total
    549,134     $ 12.27       337,707  
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
     The information required by this Item is set forth in the 2008 Proxy Statement, under the headings, “Information About our Board, Its Committees and our Corporate Governance,” “What are our processes and procedures for considering and determining executive compensation? — The Compensation Committee” and “Related Party Transactions” and is incorporated herein by this reference as if set forth in full.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
     The information required by this Item is set forth in the 2008 Proxy Statement, under the heading, “Audit Matters” and is incorporated herein by this reference as if set forth in full. The information set forth in the 2008 Proxy Statement under the heading “Report of the Audit Committee” is not incorporated herein by reference.

44


Table of Contents

PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
     (a)1. Financial Statements
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
         
Financial Statements   Page
    46  
 
    47  
 
    48  
 
    49  
 
    52  
 
    53  

45


Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
Matrixx Initiatives, Inc.
We have audited the accompanying consolidated balance sheets of Matrixx Initiatives, Inc. and subsidiaries (the “Company”) as of March 31, 2008 and March 31, 2007 and the related consolidated statements of income, changes in stockholders’ equity and cash flows for the year ended March 31, 2008, three months ended March 31, 2007 and for the years ended December 31, 2006 and 2005. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of March 31, 2008 and 2007, and the results of their operations and their cash flows for the year ended March 31, 2008, three months ended March 31, 2007, and the years ended December 31, 2006 and 2005 in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company’s internal control over financial reporting as of March 31, 2008, based on the criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated June 11, 2008 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.
/s/ Mayer Hoffman McCann, P.C.
MAYER HOFFMAN MCCANN P.C.
Phoenix, Arizona
June 12, 2008

46


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
MARCH 31, 2008 AND 2007
                 
    2008     2007  
     
ASSETS
               
Current Assets:
               
Cash and cash equivalents
  $ 27,932,672     $ 16,944,189  
Accounts receivable:
               
Trade, net of allowance for doubtful accounts of $209,377 and $429,031
    12,051,847       8,256,929  
Other receivable
    39,363        
Insurance receivable
    75,000       2,200,000  
Inventories
    11,530,060       15,458,928  
Prepaid expenses
    1,743,521       584,771  
Interest receivable
    73,904       84,191  
Income tax receivable
          1,370,277  
Deferred tax asset
    1,739,490       3,361,605  
     
Total Current Assets
    55,185,857       48,260,890  
     
 
               
Property and Equipment, at cost:
               
Office furniture and computer equipment
    1,560,403       1,356,931  
Machine tooling and manufacturing equipment
    5,330,728       5,225,020  
Laboratory furniture and equipment
    437,267       339,343  
Leasehold improvements
    514,674       350,576  
     
 
    7,843,072       7,271,870  
Less accumulated depreciation
    (2,753,222 )     (1,925,598 )
     
 
               
Net Property and Equipment
    5,089,850       5,346,272  
     
 
               
Other Assets:
               
Deposits
    379,205       221,963  
Other assets
    110,034       82,770  
Restricted cash
    500,000       500,000  
Debt issuance costs, net of accumulated amortization of $5,398 and $48,061
    8,997       7,171  
Patents, net of accumulated amortization of $582,670 and $446,002
    1,834,791       1,692,115  
Goodwill
    15,039,836       15,039,836  
     
 
               
Total Other Assets
    17,872,863       17,543,855  
     
 
               
Total Assets
  $ 78,148,570     $ 71,151,017  
     
 
               
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
 
               
Current Liabilities:
               
Accounts payable
  $ 1,307,881     $ 2,584,553  
Accrued expenses
    4,433,841       3,162,814  
Sales commissions
    533,384       372,206  
Sales returns and allowances
    1,271,791       2,391,290  
Legal liability
    1,100,000       1,045,000  
Accrued taxes
    1,927,025        
     
 
               
Total Current Liabilities
    10,573,922       9,555,863  
     
 
               
Deferred tax liability
    2,022,427       1,160,328  
     
 
               
Total Liabilities
    12,596,349       10,716,191  
 
               
Commitments and Contingencies
               
 
               
Stockholders’ Equity:
               
Preferred stock: $.001 par value, 2,000,000 shares authorized, none issued or outstanding
           
Common stock: $.001 par value, 30,000,000 shares authorized, 10,175,412 and 10,079,317 shares issued
    10,175       10,079  
Additional paid-in capital
    50,960,220       49,122,216  
Retained earnings
    22,126,374       11,698,835  
     
 
    73,096,769       60,831,130  
Less common stock held in treasury, at cost (547,769 and 53,800 shares)
    (7,544,548 )     (396,304 )
     
Total Stockholders’ Equity
    65,552,221       60,434,826  
     
Total Liabilities and Stockholders’ Equity
  $ 78,148,570     $ 71,151,017  
     
The accompanying notes are an integral part of these consolidated financial statements.

47


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
FOR THE YEAR ENDED MARCH 31, 2008, THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006 (UNAUDITED),
AND THE YEARS ENDED DECEMBER 31, 2006 AND 2005
                                         
    Year ended     Three months ended March 31,     Years ended December 31,  
    March 31,             (Unaudited)              
    2008     2007     2006     2006     2005  
               
Net sales
  $ 100,972,384     $ 19,045,754     $ 17,675,959     $ 96,230,780     $ 90,460,595  
Cost of sales
    34,532,099       7,047,655       5,865,211       32,445,499       28,201,154  
               
 
                                       
Gross Profit
    66,440,285       11,998,099       11,810,748       63,785,281       62,259,441  
 
                                       
Selling, general and administrative expenses
    46,520,327       8,730,650       10,692,507       51,946,219       54,196,370  
Research and development
    4,108,354       1,137,671       1,126,846       4,684,837       4,069,367  
               
 
                                       
Income From Operations
    15,811,604       2,129,778       (8,605 )     7,154,225       3,993,704  
               
 
                                       
Other Income (Expense):
                                       
Interest and other income
    653,422       203,374       173,911       501,845       417,724  
Interest expense
                      (116,639 )      
               
 
                                       
Total Other Income
    653,422       203,374       173,911       385,206       417,724  
               
 
                                       
Income Before Provision For Income Taxes
    16,465,026       2,333,152       165,306       7,539,431       4,411,428  
 
                                       
Provision for income taxes
    6,037,487       623,921       68,546       2,612,803       1,332,936  
               
 
                                       
Net Income
  $ 10,427,539     $ 1,709,231     $ 96,760     $ 4,926,628     $ 3,078,492  
               
 
                                       
Net Income Per Share of Common Stock:
                                       
Basic:
                                       
Weighted Average Number of Common Shares Outstanding
    9,704,579       9,749,162       9,565,963       9,620,362       9,486,288  
Net Income Per Share of Common Stock
  $ 1.07     $ 0.18     $ 0.01     $ 0.51     $ 0.32  
 
                                       
Diluted:
                                       
Weighted Average Number of Common Shares Outstanding
    10,001,307       10,031,008       10,027,666       9,965,786       9,769,922  
Net Income Per Share of Common Stock
  $ 1.04     $ 0.17     $ 0.01     $ 0.49     $ 0.32  
The accompanying notes are an integral part of these consolidated financial statements.

48


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
FOR THE YEAR ENDED MARCH 31, 2008, THE THREE MONTHS ENDED MARCH 31, 2007 AND THE YEARS ENDED
DECEMBER 31, 2006 AND 2005
                                                                 
    Series A                     Additional                     Total  
    Preferred Stock     Common Stock     Paid In     Treasury     Retained     Stockholders’  
    Shares     Amount     Shares     Amount     Capital     Stock     Earnings     Equity  
Balance at December 31, 2004
        $       9,520,198     $ 9,520     $ 42,527,862     $ (396,304 )   $ 1,984,484     $ 44,125,562  
 
Issuance of common stock upon exercise of stock options
                23,134       23       184,106                   184,129  
 
Issuance of restricted stock pursuant to the Company’s restricted stock bonus program
                56,197       56       641,052                   641,108  
 
Income tax benefit from the exercise of stock options
                            80,344                   80,344  
 
Net income
                                        3,078,492       3,078,492  
 
                                               
 
Balance at December 31, 2005
                9,599,529       9,599       43,433,364       (396,304 )     5,062,976       48,109,635  
 
Issuance of common stock upon exercise of stock options
                244,965       245       2,479,671                   2,479,916  
 
Issuance of restricted stock pursuant to the Company’s restricted stock program
                103,258       104       1,342,960                   1,343,064  
 
Income tax benefit from the exercise of stock options
                            1,077,402                   1,077,402  
 
Stock option expense pursuant to SFAS 123R
                            150,800                   150,800  
 
Net income
                                        4,926,628       4,926,628  
 
                                               
 
Balance at December 31, 2006
                9,947,752       9,948       48,484,197       (396,304 )     9,989,604       58,087,445  
 
Issuance of common stock upon exercise of stock options
                27,333       27       251,790                   251,817  
 
Issuance of restricted stock pursuant to the Company’s restricted stock program
                104,232       104       287,819                   287,923  
 
Income tax benefit from the exercise of stock options
                            80,717                   80,717  
 
Stock option expense pursuant to SFAS 123R
                            17,693                   17,693  
 
Net income
                                        1,709,231       1,709,231  
 
                                               
 
Balance at March 31, 2007
                10,079,317       10,079       49,122,216       (396,304 )     11,698,835       60,434,826  
(Continued)

49


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
FOR THE YEAR ENDED MARCH 31, 2008, THE THREE MONTHS ENDED MARCH 31, 2007 AND THE YEARS ENDED
DECEMBER 31, 2006 AND 2005
(CONTINUED)
                                                                 
    Series A                     Additional                     Total  
    Preferred Stock     Common Stock     Paid In     Treasury     Retained     Stockholders’  
    Shares     Amount     Shares     Amount     Capital     Stock     Earnings     Equity  
Issuance of common stock upon exercise of stock options
        $       59,767     $ 60     $ 611,083     $     $     $ 611,143  
 
Issuance of restricted stock pursuant to the Company’s restricted stock program
                58,760       58       1,294,506                   1,294,564  
 
Purchase of treasury stock
                                  (7,463,393 )           (7,463,393 )
 
Retirement of treasury stock
                (22,432 )     (22 )     (315,127 )     315,149              
 
Income tax benefit from the exercise of stock options
                            231,401                   231,401  
 
Stock option expense pursuant to SFAS 123R
                            16,141                   16,141  
 
Net income
                                        10,427,539       10,427,539  
 
                                               
 
Balance at March 31, 2008
        $       10,175,412     $ 10,175     $ 50,960,220     $ (7,544,548 )   $ 22,126,374     $ 65,552,221  
 
                                               
The accompanying notes are an integral part of these consolidated financial statements.

50


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED MARCH 31, 2006
(UNAUDITED)
                                                                 
    Series A                     Additional                     Total  
    Preferred Stock     Common Stock     Paid In     Treasury     Retained     Stockholders’  
    Shares     Amount     Shares     Amount     Capital     Stock     Earnings     Equity  
Balance at December 31, 2005
        $       9,599,529     $ 9,599     $ 43,433,364     $ (396,304 )   $ 5,062,976     $ 48,109,635  
 
Issuance of common stock upon exercise of stock options
                117,765       118       1,256,264                   1,256,382  
 
Issuance of restricted stock pursuant to the Company’s restricted stock program
                100,188       100       923,871                   923,971  
 
Stock option expense pursuant to SFAS 123R
                            54,967                   54,967  
 
Net income
                                        96,760       96,760  
 
                                               
 
Balance at March 31, 2006
        $       9,817,482     $ 9,817     $ 45,668,466     $ (396,304 )   $ 5,159,736     $ 50,441,715  
 
                                               
The accompanying notes are an integral part of these consolidated financial statements.

51


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEAR ENDED MARCH 31, 2008, THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006 (UNAUDITED),
AND THE YEARS ENDED DECEMBER 31, 2006 AND 2005
                                         
    Year ended     Three months ended March 31,     Years ended December 31,  
    March 31,             (Unaudited)              
    2008     2007     2006     2006     2005  
Cash Flows From Operating Activities
                                       
Net income
  $ 10,427,539     $ 1,709,231     $ 96,760     $ 4,926,628     $ 3,078,492  
Adjustments to reconcile net income to net cash provided (used) by operating activities:
                                       
Depreciation
    1,057,299       491,520       138,429       630,599       345,761  
Amortization
    149,130       40,346       48,448       170,691       83,415  
Provision for bad debts
    (219,654 )     18,335       (277,443 )     (232,219 )     87,675  
Deferred income taxes
    2,484,214       539,333       (9,348 )     1,540,738       (88,142 )
Common stock issued for compensation
    1,542,106       386,333       978,938       2,571,266       641,108  
Changes in assets and liabilities:
                                       
Accounts receivable
    (3,614,627 )     15,598,763       20,667,204       6,312,460       (17,655,917 )
Insurance receivable
    2,125,000       (797,033 )           3,397,033       (4,800,000 )
Interest receivable
    10,287       (37,937 )     (43,401 )     78,279       (66,875 )
Income tax receivable
    1,370,277                   (1,370,277 )      
Inventories
    3,928,868       1,326,416       (2,723,980 )     (7,982,209 )     (1,561,701 )
Prepaid expenses and other
    (1,186,014 )     169,532       81,644       58,767       (8,254 )
Accounts payable
    (1,276,672 )     (12,729,552 )     (4,303,561 )     6,572,454       4,042,335  
Accrued expenses
    3,359,230       (3,175,957 )     (3,459,475 )     (4,546,972 )     3,471,133  
Legal liability
    55,000       (126,500 )     (12,000,000 )     (12,073,500 )     13,245,000  
Sales returns and allowances
    (1,119,499 )     (340,830 )     (1,206,721 )     (1,148,432 )     1,275,292  
               
 
                                       
Net Cash Provided (Used) By Operating Activities
    19,092,484       3,072,000       (2,012,506 )     (1,094,694 )     2,089,322  
               
 
                                       
Cash Flows From Investing Activities
                                       
Capital expenditures
    (800,877 )     (310,750 )     (67,193 )     (4,997,736 )     (1,867,296 )
Deposits and other
    (436,586 )     (16,500 )     (38,974 )     802,846       (788,119 )
Restricted cash
                      4,500,000        
               
 
                                       
Net Cash Provided (Used) By Investing Activities
    (1,237,463 )     (327,250 )     (106,167 )     305,110       (2,655,415 )
               
 
                                       
Cash Flows From Financing Activities:
                                       
Proceeds from borrowing
                      4,000,000        
Principal payments on notes payable
                      (4,000,000 )      
Debt issuance costs
    (14,288 )           (2,939 )     (9,381 )     (45,851 )
Issuance of common stock
    611,143       251,817       1,256,382       2,479,916       184,129  
Purchase of treasury stock
    (7,463,393 )                        
               
 
                                       
Net Cash (Used) Provided By Financing Activities
    (6,866,538 )     251,817       1,253,443       2,470,535       138,278  
               
 
                                       
Net Increase (Decrease) in Cash and Cash Equivalents
    10,988,483       2,996,567       (856,230 )     1,680,951       (427,815 )
 
                                       
Cash and Cash Equivalents at Beginning of Period
    16,944,189       13,947,622       12,266,671       12,266,671       12,694,486  
               
 
                                       
Cash and Cash Equivalents at End of Period
  $ 27,932,672     $ 16,944,189     $ 11,401,441     $ 13,947,622       12,266,671  
               
 
                                       
Supplemental Disclosure of Cash Flow Information:
                                       
Cash paid during the period for:
                                       
Interest
  $     $     $     $ 115,222     $  
Income taxes
                860,790       2,021,243       814,164  
 
Supplemental Disclosure of Noncash Financing Activities:
                                       
Retirement of treasury stock
  $ 315,149     $     $     $     $  
The accompanying notes are an integral part of these consolidated financial statements.

52


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Organization and Summary of Significant Accounting Policies
   Organization
     Gum Tech International, Inc. (the “Company”) was incorporated in Utah on February 4, 1991 to develop, market and distribute specialty chewing gum products for branded and private label customers, as well as products marketed under the Company’s brand. The Company sold its gum operations in July 2001. On June 18, 2002, the Company completed its previously announced plans to reincorporate in Delaware and change its name to Matrixx Initiatives, Inc. (“Matrixx” or the “Company”). The reincorporation and name change were effectuated through a merger of the Company (then Gum Tech International, Inc.) with and into its wholly-owned Delaware subsidiary, Matrixx Initiatives, Inc. The timing of the merger (including the resulting reincorporation and name change) immediately followed the receipt of approval of the Company’s shareholders at its regularly scheduled annual meeting held on such date. The authorized capital stock of Matrixx consists of (i) 30,000,000 shares of common stock, $.001 par value, (“common stock”), and (ii) 2,000,000 shares of preferred stock, $.001 par value. Upon the effectiveness of the merger, each share of Gum Tech International, Inc. common stock issued and outstanding immediately before the merger was extinguished and converted into one issued and outstanding share of Matrixx common stock. All dollar amounts have been retroactively restated for the change in the capital structure.
     The Company’s sole business segment in the fiscal year ended March 31, 2008, three-month transition period ended March 31, 2007, and calendar years 2006 and 2005, was developing, marketing and selling over the counter products with an emphasis on those that utilize unique or novel delivery systems through a wholly-owned subsidiary, Zicam, LLC. During 2005, we formed Zicam Swab Products, LLC (ZSP) to purchase the dry handle swab technology from a third party. During 2006, we formed Matrixx Oral Care, LLC (MOC), subsequently renamed Zicare, LLC (Zicare), to pursue development of an over-the-counter oral care product. In May 2008, we formed Zicam Canada, Inc. to commercialize sales of Zicam products in Canada.
   Principles of Consolidation
     The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Zicam, ZSP, and Zicare. All significant intercompany accounts and transactions have been eliminated.
   Change of Fiscal Year
     Because of the extreme seasonality in the Company’s business, on February 9, 2007, the Company’s Board of Directors approved a change in the Company’s fiscal year end from December 31 to March 31 in order to better align the Company’s operations and financial results with the entire cold season. The three month period ended March 31, 2007 was the Company’s transition period and the Company’s new fiscal year began April 1, 2007 and ended March 31, 2008. All comparative presentations for the three-months ended March 31, 2006 are unaudited.
   Cash and Cash Equivalents
     For purposes of the consolidated financial statements, the Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits in each institution are insured in limited amounts by the Federal Deposit Insurance Corporation (FDIC).
   Accounts Receivable and Allowance for Doubtful Accounts
     Accounts receivable are recorded at the invoice amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable; however, changes in circumstances relating to accounts receivable may result in a requirement for additional allowances in the future. The Company determines the allowance based on historical write-off experience, current market trends and, for larger accounts, the ability to pay outstanding balances. Past due balances over 90 days and other higher risk amounts are reviewed individually and collectively. In addition, the Company maintains a reserve for all invoices by applying a percentage based on historical trends. Account balances are charged against the allowance after all collection efforts have been exhausted and the potential for recovery is considered remote. During fiscal 2008, we determined that our allowance for bad debt exceeded the amount of loss

53


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
that would likely be incurred and we reduced the allowance amount by approximately $250,000, which reduced selling, general and administrative (“SG&A”) expenses by an equal amount.
   Inventories
     Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out pricing method.
   Property and Equipment
          Depreciation of the primary asset classifications is calculated based on the following estimated useful lives using the straight-line method.
         
Classification   Useful Life in Years
Machine tooling and manufacturing equipment
    3-7  
Office furniture and computer equipment
    3-5  
Laboratory equipment and furniture
    3-5  
Leasehold improvements
    2-5  
     For the twelve months ended March 31, 2008 depreciation of property and equipment was $1,075,299. In addition, for the three months ended March 31, 2007 and 2006 and the years ended December 31, 2006 and 2005, depreciation of property and equipment charged to selling, general and administrative expenses was $491,520, $138,429, $630,599, and $345,761, respectively.
   Long-Lived Assets
     When facts and circumstances indicate that the carrying value of long-lived assets may be impaired, an evaluation of the recoverability is performed by comparing the carrying value of the assets to the estimated undiscounted net future cash flows. A forecast showing lack of long-term profitability, a significant decline in market share, or a current period operating or cash flow loss combined with a history of operating or cash flow losses are conditions, among others, that would trigger an impairment assessment of the carrying amount of enterprise goodwill.
     Upon indication that the carrying value of such assets may not be recoverable, the Company recognizes an impairment loss by a charge against current operations. If an impairment exists, an impairment charge would be determined by comparing the carrying amount of the assets to the applicable estimated future cash flows, discounted at a risk-adjusted rate or market appraisals. In addition, the remaining amortization period for the impaired asset would be reassessed and revised if necessary.
   Intangible Assets
     In accordance with Statement of Financial Accounting Standards (“SFAS”) No. 142, “Goodwill and Other Intangible Assets” (“SFAS 142”), goodwill is assessed at least annually for impairment using the fair value methodology. The Company completed its annual assessment in the quarter ended September 30, 2007. There were no impairments recorded in any period presented.
     The original Cold Remedy patent is being amortized using the straight-line method over the remaining term of the patent at the date of purchase of 16.75 years. The estimated aggregate amortization expense for the Company’s Cold Remedy patent is $67,081 on an annual basis for each of the next five years. Amortization expense for the Cold Remedy patent was $67,081 for the year ended March 31, 2008; $16,770 for the three months ended March 31, 2007 and 2006; and, $67,081 for each of the years ended December, 31, 2006 and 2005. The patent acquired on October 31, 2005 related to the Zicam Cold Remedy dry handle swab products is being amortized using the straight-line method over the remaining term of the patent, which, at the date of purchase was 14.88 years. The estimated aggregate amortization expense for the Zicam Cold Remedy dry handle swab patent is $76,200 on an annual basis for each of the next five years. Amortization expense was $69,588 for the year ended March 31, 2008, $15,743 for the three months ended March 31, 2007 and 2006, and $62,971 and $10,495 for the years ended December 31, 2006 and 2005, respectively.

54


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
     The Company recorded $8,748 in calendar 2006 for debt issuance costs related to the $500,000 letter of credit associated with the product liability insurance policy that began in April 2006. The Company recorded $23,327 in 2005 for debt issuance costs related to the $5.0 million letter of credit established for the self-structured product liability insurance policy that began in April 2004. These costs are amortized over one year. The Company amortizes the debt issuance costs associated with the Company’s Comerica Bank credit facility over the term of the facility. Debt issuance costs of $14,395 were recorded in fiscal 2008 for the renewal of the credit facility with a term through June 30, 2009. The Company recorded $12,569 in amortization expense during the year ended March 31, 2008, $7,832 in the three months ended March 31, 2007, and $31,893 in calendar year 2006 for amortization of expenses related to the Company’s Comerica Bank credit facility. The Company recorded $31,287 in 2005 for amortization of expenses related to the letter of credit and the credit facility.
     Goodwill is considered to have an indefinite life and, therefore, it is not amortized, but instead is tested for impairment at least annually. There was no impairment recorded in the year ended March 31, 2008, three months ended March 31, 2007, or in calendar years 2006 or 2005.
   Revenue Recognition
     The Company recognizes revenue from product sales when the risks and rewards of ownership have transferred to the customer. Transfer of risks and rewards is considered to have occurred upon shipment of the finished product. Sales incentives, promotional allowances and returns are estimated and recognized as a reduction from revenue at the date of shipment based upon historical activity and current agreements with customers. The Company evaluates these estimates on a monthly basis and revises them as necessary.
   Stock-Based Compensation
     Effective January 1, 2006, the Company adopted SFAS No. 123R (Revised 2004), “Share-Based Payment, which revises SFAS No. 123, “Accounting for Stock-Based Compensation”, and supersedes Accounting Principles Boards Opinion No. 25, “Accounting for Stock Issued to Employees.” SFAS No. 123R requires the Company to measure the cost of services received in exchange for equity instruments based on the grant-date fair value of the award, with that cost recognized to expense over the requisite service or vesting period. SFAS No. 123R allows for the use of the Black-Scholes or a lattice option-pricing model to value such equity instruments. The Company uses the Black-Scholes option-pricing model in valuing such equity instruments. Upon adoption, the Company transitioned to SFAS No. 123R using the Modified Prospective Application (MPA) transition method, whereby compensation cost is recognized for new awards and awards modified after the effective date, and to that portion of outstanding awards for which part or all of the requisite service will be rendered on or after the effective date. Prior periods’ stock-based compensation for option plan activity is still presented on a pro forma basis. As a result of the adoption of SFAS No. 123R, in calendar year 2006 the Company recognized pre-tax charges of $150,800 as compensation expense, approximately $93,000 after tax, related to unvested options as of January 1, 2006. In addition, for the three months ended March 31, 2007 and 2006 the Company recognized pre-tax charges of $17,700 and $55,000, respectively, approximately $11,000 and $34,000 after tax, respectively. During the fiscal year ended March 31, 2008, the Company recognized pre-tax charges of $16,000, approximately $9,800 after tax. The earnings per share impact in all of those periods was immaterial. The Company does not expect to recognize any additional charges in association with stock options as the Company anticipates future equity compensation will be in the form of restricted stock grants instead of options. These charges do not affect the Company’s cash position.
     On February 7, 2005, the Company’s Compensation Committee approved a new executive stock ownership requirement and approved the immediate vesting of all outstanding stock options previously granted under the Company’s option plans, including those granted to executive officers and directors, for which the option exercise price was above the closing price on February 7, 2005.
     The following table details the effect on net income and earnings per share as if compensation expense had been recorded for the year ended December 31, 2005 based on the fair value method under SFAS No. 123. The reported and pro forma net income and earnings per share for the three months ended March 31, 2007 and year ended December 31, 2006 is the same since share-based compensation expense is calculated under the provisions of SFAS No. 123R.

55


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
         
Net income applicable to common shareholders, as reported
  $ 3,078,492  
Add stock-based employee compensation expense included in net earnings, net of tax
     
Less stock-based employee compensation expense determined under fair value based methods for all awards, net of related tax effects
    1,546,183  
 
     
Proforma Net Income
  $ 1,532,309  
 
     
Net income per share of common stock:
       
Basic:
       
As reported
  $ 0.32  
Pro forma
  $ 0.16  
Diluted
       
As reported
  $ 0.32  
Pro forma
  $ 0.16  
     The fair value for options was estimated at the date of grant using the Black-Scholes option pricing model with the following assumptions for the year ended December 31, 2005:
         
    2005  
Risk-free interest rate
    3.66 %
Expected life
  5.00 years
Expected volatility
    61.40 %
Expected dividend yield
    0 %
     The Company has granted restricted stock to directors, officers, and management employees as part of its overall compensation plan. Compensation expense is based on the fair value of the shares on the date of their grant (as determined by the closing stock price on the grant date), and is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized in the year ended March 31, 2008, for restricted stock awards previously granted, was approximately $1.2 million, or $750,000 after tax. During the three-month transition period ended March 31, 2007, the Company recognized approximately $281,900, or approximately $173,000 after tax, for compensation expense related to restricted stock awards. During the year ended December 31, 2006 compensation expense for restricted stock awards was approximately $736,000. Also, during the year ended March 31, 2008, 4,544 shares of restricted stock were issued to two directors, in lieu of cash, under the Directors Restricted Stock Purchase Program for quarterly director compensation.
Comprehensive Income
     Comprehensive income consists of net income (loss) and other gains and losses affecting stockholders’ equity that, under accounting principles generally accepted in the United States of America, are excluded from net income (loss). Such items consist primarily of unrealized gains and losses on marketable equity securities and foreign translation gains and losses. The Company has not had any such items in the prior three years and, consequently, net income (loss) and comprehensive income (loss) are the same.
Shipping and Handling Costs
     Shipping and handling costs are expensed as incurred and included in cost of sales.
Income Taxes
     Deferred income taxes are provided for temporary differences between the financial reporting and tax basis of assets and liabilities using enacted tax laws and rates for the years when the differences are expected to reverse.

56


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Research and Development
     Research and development costs are expensed as incurred.
Marketing and Advertising
     The Company expenses marketing and advertising costs as incurred. Marketing expense was: $29,123,368 and $29,854,733 for the years ended March 31, 2008 and 2007, respectively; $5,014,921 and $6,698,927 for the three months ended March 31, 2007 and 2006, respectively; and $31,538,778 and $25,002,100 for the years ended December 31, 2006 and 2005, respectively.
Net Income Per Share of Common Stock
     Basic earnings per share is calculated using the weighted average number of common shares outstanding. Diluted earnings per share is computed on the basis of the weighted average number of common shares outstanding plus the dilutive effect of outstanding stock options using the treasury stock method.
     The schedule below summarizes the elements included in the calculation of basic and diluted earnings per common share for the year ended March 31, 2008, three months ended March 31, 2007 and 2006, and the years ended December 31, 2006 and 2005. Options, warrants and other incremental shares to purchase 177,000, 232,000, and 264,752 shares of common stock at March 31, 2008 and 2007, and December 31, 2005, respectively, were excluded from the computation of diluted earnings per share because their effect would be anti-dilutive. The shares were anti-dilutive because the share exercise price exceeded the average market price of the common stock during the period. There were no anti-dilutive shares at December 31, 2006 or March 31, 2006.
                                         
    Year Ended March 31,     Three Months Ended March 31,     Years Ended December 31,  
    2008     2007     2006     2006     2005  
Net income applicable to common shareholders
  $ 10,427,539     $ 1,709,231     $ 96,760     $ 4,926,628     $ 3,078,492  
 
                             
Weighted average common shares outstanding — Basic
    9,704,579       9,749,162       9,565,963       9,620,362       9,486,288  
 
                                       
Dilutive securities
    296,728       281,846       461,703       345,424       283,634  
 
                             
Weighted average common shares outstanding — Diluted
    10,001,307       10,031,008       10,027,666       9,965,786       9,769,922  
 
                             
Net Income per common share:
                                       
Basic
  $ 1.07     $ 0.18     $ .01     $ 0.51     $ 0.32  
Diluted
  $ 1.04     $ 0.17     $ .01     $ 0.49     $ 0.32  
Estimates
     The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Recently Issued Accounting Standards
     In July 2006, the Financial Accounting Standards Board (“FASB”) issued Interpretation No. 48, "Accounting for Uncertainty in Income Taxes” (FIN 48), effective for fiscal years beginning after December 15, 2006. The interpretation applies to tax positions within the scope of SFAS No. 109, Accounting for Income Taxes. Interpretation 48 is a two-step process for recognition and evaluation of uncertain tax positions. It requires the Company to assess whether a tax position is “more-likely-than-not” to be sustained based on its technical merits and then to determine the amount of the tax position to be recognized in the financial statements. The Company implemented FIN 48 beginning January 1, 2007. Adoption of FIN 48 did not have a material impact on our earnings,

57


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
financial position, or cash flows. As of March 31, 2008, the Company believes that all of its tax positions are more likely than not to be sustained based on their technical merits.
     In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements” (SFAS 157), effective for fiscal years beginning after November 15, 2007. SFAS 157 provides guidance on how to measure assets and liabilities that use fair value, and expands disclosure about fair value measurement. SFAS 157 will apply whenever another GAAP standard requires (or permits) assets or liabilities to be measured at fair value but does not expand the use of fair value to any new circumstances. The Company has adopted SFAS 157 as of April 1, 2008. Adoption of SFAS 157 did not have a material impact on our earnings, financial position, or cash flows.
     In September 2006, the U.S. Securities and Exchange Commission issued Staff Accounting Bulletin No. 108 (SAB 108), “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements.” SAB 108 provides guidance on the consideration of the effects of prior year misstatements in quantifying current year misstatements in determining whether the current year’s financial statements are materially misstated. SAB 108 is effective for fiscal years ending after November 15, 2006. The Company has adopted SAB 108 as of December 31, 2006, and its adoption did not have an impact on the Company’s consolidated financial statements.
     In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities: Including an amendment of FASB Statement No. 115” (SFAS 159). SFAS 159 permits entities to measure many financial instruments and certain other items at fair value with changes in fair value reported in earnings. The FASB issued SFAS 159 to mitigate earnings volatility that arises when financial assets and liabilities are measured differently, and to expand the use of fair value measurement for financial instruments. SFAS 159 is effective as of the beginning of the first fiscal year that begins after November 15, 2007. We adopted SFAS 159 beginning April 1, 2008. Adoption of SFAS 159 did not have a material impact on our earnings, financial position, or cash flows.
     In December 2007, the FASB issued SFAS No. 141R, “Business Combinations Statement 141R,” a replacement of SFAS No. 141. SFAS 141R is effective for fiscal years beginning on or after December 15, 2008 and applies to all business combinations. SFAS 141R provides that, upon initially obtaining control, an acquirer shall recognize 100% of the fair values of acquired assets, including goodwill, and assumed liabilities, with only limited exceptions, even if the acquirer has not acquired 100% of its target. Additionally, SFAS 141R changes current practice, in part, as follows: (1) contingent consideration arrangements will be fairly valued at the acquisition date and included on that basis in the purchase price consideration; (2) transaction costs will be expensed as incurred, rather than capitalized as part of the purchase price; (3) pre-acquisition contingencies, such as legal issues, will generally have to be accounted for in purchase accounting at fair value; and (4) in order to accrue for a restructuring plan in purchase accounting, the requirements in SFAS No. 146, “Accounting for Costs Associated with Exit or Disposal Activities,” would have to be met at the acquisition date. While there is no expected impact to our consolidated financial statements on the accounting for acquisitions completed prior to April 1, 2009, the adoption of SFAS 141R on April 1, 2009 could materially change the accounting for business combinations consummated subsequent to that date.
     In March 2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities — an amendment of FASB Statement No. 133” (“SFAS 161”), which modifies and expands the disclosure requirements for derivative instruments and hedging activities. SFAS 161 requires that objectives for using derivative instruments be disclosed in terms of underlying risk and accounting designation and requires quantitative disclosures about fair value amounts and gains and losses on derivative instruments. It also requires disclosures about credit-related contingent features in derivative agreements. SFAS 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application encouraged. SFAS 161 encourages, but does not require, comparative disclosures for earlier periods at initial adoption. The adoption of SFAS 161 is not expected to have a material impact on our consolidated financial condition or results of operations.

58


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
2. Inventories
     Inventories consist of the following at March 31, 2008 and 2007:
                 
    March 31,     March 31,  
    2008     2007  
Raw materials and packaging
  $ 3,887,906     $ 4,391,903  
Finished goods
    7,642,154       11,067,025  
 
           
Total
  $ 11,530,060     $ 15,458,928  
 
           
3. Current Notes Payable
     The Company has an $8.0 million credit facility with Comerica Bank that was renewed in July 2007, until July 2009. The interest rate under the renewed credit facility is prime minus 0.25% (or 5.0% at March 31, 2008) collateralized by accounts receivable, inventory, property and equipment, intangible assets and other assets of the Company. The line also contains various financial covenants regarding liquidity, tangible net worth, and other financial ratios. Also, the Company cannot incur a loss for any two consecutive quarters and the Company cannot incur a loss for any fiscal year. The Company is also restricted from paying dividends without the lender’s consent. We did not have any borrowings under the credit facility during the year ended March 31, 2008, or three months ended March 31, 2007. In July 2006, we borrowed $4 million under the facility to support our working capital requirements in the third calendar quarter of 2006. We repaid the debt in the quarter ended December 31, 2006. We are in compliance with the earnings and financial covenants contained in the credit facility.
4. Reserves
     The following schedules summarize the activity in the reserves for sales returns and allowances and allowance for doubtful accounts for the year ended March 31, 2008, three months ended March 31, 2007, and each of the years ended 2006 and 2005:
                                 
            Additions            
    Balance at   Charged to           Balance at
    Beginning of   Costs and           End of
Description   Period   Expenses   Deductions   Period
Reserves for Sales Returns and Allowances
                               
December 31, 2005
  $  2,605,260     $  11,796,458     $  10,521,166     $  3,880,552  
December 31, 2006
    3,880,552       14,871,924       16,020,356       2,732,120  
March 31, 2007
    2,732,120       2,909,400       3,250,230       2,391,290  
March 31, 2008
    2,391,290       15,432,925       16,699,644       1,124,571  
                                 
            Additions            
    Balance at   Charged to           Balance at
    Beginning of   Costs and           End of
Description   Period   Expenses   Deductions   Period
Allowance for Doubtful Accounts
                               
December 31, 2005
  $ 555,240     $ 92,568     $ 4,893     $ 642,915  
December 31, 2006
    642,915       97,286       329,505       410,696  
March 31, 2007
    410,696       18,827       492       429,031  
March 31, 2008
    429,031       20,676       240,330       209,377  
5. Income Taxes
     The components of the provision for income taxes for the year ended March 31, 2008, three months ended March 31, 2007 and 2006, and the years ended December 31, 2006, and 2005, are as follows:

59


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
                                         
    Year Ended March 31,     Three Months Ended March 31,     Years Ended December 31,  
    2008     2007     2006     2006     2005  
Current:
                                       
Federal
  $ 2,094,047     $ 66,041     $ 60,281     $ 881,511     $ 1,107,248  
State
    390,167       18,548       8,265       190,554       394,137  
 
                             
Total
    2,484,214       84,589       68,546       1,072,065       1,501,385  
 
                             
 
                                       
Deferred:
                                       
Federal
    3,013,768       504,901             1,137,312       131,506  
State
    539,505       34,431             403,426       36,943  
 
                             
Total
    3,553,273       539,332             1,540,738       168,449  
 
                             
 
                                       
Total Provision For Income Taxes
  $ 6,037,487     $ 623,921     $ 68,546     $ 2,612,803     $ 1,332,936  
 
                             
     The provision for income taxes reconciles to the amount computed by applying the federal statutory rate to income before the provision for income taxes as follows:
                                         
    Year Ended March 31,     Three Months Ended March 31,     Years Ended December 31,  
    2008     2007     2006     2006     2005  
Federal statutory rate
    34 %     34 %     34 %     34 %     34 %
State income taxes, net of federal benefits
    5       5       5       5       5  
Current period tax credits
    (1 )                   (2 )     (11 )
Charitable contributions
    (1 )     (12 )           (3 )      
Other
                2             2  
Net operating loss carryover
                             
 
                             
Total
    37 %     27 %     41 %     34 %     30 %
 
                             
     The components of deferred tax assets and liabilities as of March 31, 2008 and 2007 are as follows:
                 
    2008     2007  
Current deferred tax assets
               
Net operating loss carryforwards
  $     $ 555,600  
Reserves and accrued expenses
    718,800       1,165,000  
Charitable contributions carryforward
          1,047,300  
Accrued legal liabilities
    423,500       402,300  
Reserve for bad debts
    80,600       165,200  
Research and development credit
          140,000  
Inventory valuation reserve
    516,590       733,205  
 
           
Total current deferred tax assets
    1,739,490       4,208,600  
 
               
Current deferred tax liabilities
               
Accrued receivable
          (847,000 )
 
           
 
Net current deferred tax assets
  $ 1,739,490     $ 3,361,605  
 
           
 
Non-current deferred tax assets
               
Restricted stock compensation
    828,500       980,200  
Other
          18,062  
 
           
Total non-current deferred tax assets
  $ 828,500     $ 998,262  
 
               
Non-current deferred tax liabilities
               
Amortization of intangible assets
    (2,463,827 )     (2,058,900 )
Depreciation
    (387,100 )     (99,690 )
 
           
Total non-current deferred tax liabilities
    (2,850,927 )     (2,158,590 )
 
           
 
               
Net non-current deferred tax liabilities
  $ (2,022,427 )   $ (1,160,328 )
 
       

60


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
     The Company records a valuation allowance for certain temporary differences for which it is more likely than not that it will not receive future tax benefits. The Company assesses its past earnings history and trends, sales backlog and projections of future net income. As of March 31, 2008 and 2007, the Company did not record a valuation allowance.
     The Company’s policy is to classify income tax penalties and interest as income taxes in its financial statements. During the year ended March 31, 2008, the Company did not incur any penalties or interest. At March 31, 2008, the Company did not have any unrecognized tax benefits.
     The tax benefits associated with employee exercises of non-qualified stock options and disqualifying dispositions of stock acquired with incentive stock options reduced income taxes currently payable. The Company has determined that it is more likely than not that the amounts will be realized and has recorded benefits charged to additional paid-in-capital for the year ended March 31, 2008, three months ended March 31, 2007, and the years ended December 31 2006 and 2005 of $231,401, $80,717, $1,077,402, and $80,344, respectively.
     At December 31, 2006, the Company had a $1.4 million loss carryforward due to the settlement of the consolidated Arizona litigation in 2006. The Company exhausted this carryforward in fiscal year 2008.
6. Preferred Stock
     The authorized preferred stock of the Company consists of 2,000,000 shares, $0.001 par value. The preferred stock may be issued in separate series from time to time as the Board of Directors of the Company may determine by resolution, unless the nature of a particular transaction and applicable statutes require shareholder approval. The rights, preferences and limitations of each series of preferred stock may differ, including without limitation, the rate of dividends, method and nature of payment of dividends, terms of redemption, amounts payable on liquidation, sinking fund provisions (if any), conversion rights (if any), and voting rights.
7. Stockholders’ Equity
Stock Repurchase Plan
     In April 2004, the Company’s Board of Directors authorized a Common Stock Repurchase Program for up to 1.0 million shares of the Company’s common stock. During fiscal 2008, the Company purchased 493,969 shares of common stock on the open market at an aggregate cost of $7,148,245. In addition, the Company repurchased 22,432 shares of common stock at an aggregate cost of $315,148, from employees and directors to satisfy tax withholding requirements associated with vested restricted stock. No common stock was repurchased during the three months ended March 31, 2007 or the years ended December 31, 2006 and 2005.
Shareholder Rights Plan
     In July 2002, the Board of Directors of the Company adopted a shareholder rights plan in the form of a Rights Agreement dated as of July 22, 2002 by and between the Company and Corporate Stock Transfer, Inc., as Rights Agent (the “Rights Agreement”). On July 12, 2002, the Board of Directors of the Company declared a dividend of one preferred share purchase right (a “Right”) for each outstanding share of common stock. The dividend was paid on July 22, 2002 to the Company’s stockholders of record on that date. The Rights also apply to, and will be issued in the same proportion in connection with, all future common stock issuances until the Distribution Date (defined below) or the expiration or earlier redemption or exchange of the Rights. Each Right permits the registered holder thereof to purchase from the Company, at any time after the Distribution Date, one one-thousandth of a share of the Company’s Series A Junior Participating Preferred Stock for a purchase price of $50.79 per such one one-thousandth of a share, subject to certain possible adjustments provided for in the Rights Agreement. The Board of Directors of the Company has authorized the issuance of up to 20,000 shares of Series A Junior Participating Preferred Stock upon the exercise of Rights.
     Initially the Rights will be attached to all certificates representing shares of common stock then outstanding, and no separate Rights certificates will be distributed. The Rights will separate from the common stock upon the earlier

61


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
to occur of (i) 10 days after the public announcement of a person’s or group of affiliated or associated persons having acquired beneficial ownership of 15% or more of the outstanding common stock (such person or group being an “Acquiring Person”), or (ii) 10 business days (or such later date as the Company’s Board may determine) following the commencement of, or announcement of an intention to make, a tender offer or exchange offer for the common stock, the consummation of which would result in a person or group’s becoming an Acquiring Person (the earlier of such dates being the “Distribution Date”). The Rights are not exercisable until the Distribution Date. If any person (or group of persons) becomes an Acquiring Person, except in a tender or exchange offer which is for all outstanding common stock at a price and on terms which a majority of the Company’s Board determines to be adequate and in the best interests of the Company, its shareholders and other relevant constituencies (other than such Acquiring Person, its affiliates and associates), each holder of a Right will thereafter be entitled to acquire, for each Right so held, one share of common stock for a purchase price equal to 50% of the then current market price for such share of common stock. All Rights beneficially owned by an Acquiring Person or any affiliate or associate thereof will be null and void and not exercisable. The Rights expire on July 22, 2012 provided that, prior to a person (or group of persons) becoming an Acquiring Person, the Company may redeem the Rights for $0.01 per Right. All of the provisions of the Rights Agreement may be amended before the Distribution Date by the Board of Directors of the Company for any reason it deems appropriate. After the Distribution Date, the provisions of the Rights Agreement may be amended by the Board in order to cure any ambiguity, defect or inconsistency, to make changes which do not adversely affect the interest of Rights (excluding the interest of any Acquiring Person) or, subject to certain limitations, to shorten or lengthen any time period under the Rights Agreement.
Directors Restricted Stock Purchase Program
     In 2002, the Company established a Director Restricted Stock Purchase Program (the “Program”). Under the Program the number of shares to which the Director will be entitled is equal to the cash portion of compensation payable to him/her for Directors fees by the Company that he/she wishes to apply to the purchase of shares under the Program divided by 80% of the closing price of the Company’s stock price on the date the cash consideration would be paid. Shares issued under the Program are restricted until the first to occur of (i) the expiration of three years from the date the shares are issued, (ii) a change in control of the Company, and (iii) the Director’s death, disability, or mandatory retirement.
8. Stock Options
2001 Long-Term Incentive Plan
     In November 2001, the Company adopted the 2001 Long-Term Incentive Plan (the “2001 Plan”). The 2001 Plan provides for the grant of incentive stock options, non-qualified options, restricted common stock, performance based awards, tandem awards and substitute awards. In May 2005, shareholders approved an amendment to the 2001 Plan increasing the number of shares authorized for issuance under the Plan from 1,000,000 shares to 1,500,000 shares.
     The following table contains information on the stock options under the Company’s 2001 Plan for the year ended March 31, 2008. The outstanding options expire from October 2008 to July 2011.
                                 
            Weighted-     Weighted-Average        
            Average     Remaining Contractual     Aggregate Intrinsic  
Options   Shares     Exercise Price     Term     Value  
Options outstanding at March 31, 2007
    653,901     $ 12.47                  
Granted
    -                          
Exercised
    (59,767 )     10.23                  
Cancelled
    (45,000 )     17.90                  
 
                               
 
                             
Options outstanding at March 31, 2008
    549,134     $ 12.27     2.88 years   $ 1,881,576  
 
                             
 
Exercisable at March 31, 2008
    549,134     $ 12.27     2.88 years   $ 1,881,576  
 
                             

62


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
     No options were granted in the year ended March 31, 2008, three months ended March 31, 2007 or calendar 2006. The weighted average fair value of options granted was $6.05 in 2005.
     The total intrinsic value of options exercised during the year ended March 31, 2008, three months ended March 31, 2007 and 2006 and the fiscal years ended December 31, 2006 and 2005 was $569,000, $210,000, $1.6 million, $3.0 million, and $197,000, respectively. The total fair value of shares vested during the fiscal years ended December 31, 2006 and 2005 was $1.5 million and $6.2 million, respectively. No shares vested during the year ended March 31, 2008 or three months ended March 31, 2007.
     Cash received from the exercise of options for the year ended March 31, 2008 was approximately $611,000. The related tax benefit realized was approximately $231,000.
     A summary of the Company’s restricted stock awards is presented below:
                 
          Weighted-Average Grant-  
    Shares     Date Fair Value  
Nonvested at March 31, 2007
    260,620     $ 16.68  
Granted
    61,510       15.77  
Vested
    (118,301 )     14.67  
Forfeited
    (2,750 )     20.58  
 
             
Nonvested at March 31, 2008
    201,079     $ 17.45  
 
             
     The weighted average fair value of restricted stock awards granted for the three months ended March 31, 2007 and 2006, and the years ended December 31, 2006 and 2005 was $16.51, $21.66, $21.51, and $11.41, respectively.
     As of March 31, 2008, the Company had approximately $1.9 million of unrecognized compensation expense related to non-vested restricted stock awards that is expected to be recognized over a weighted-average period of approximately 19 months.
     The fair value of the Company’s restricted stock awards was determined using the closing price of the Company’s shares on the respective grant dates.
   Other Stock Option Information
     The following table summarizes information about the Company’s stock-based compensation plan at March 31, 2008:
                                         
    Options Outstanding   Options Exercisable
            Weighted                
            Average   Weighted            
            Remaining   Average           Weighted
        Range of   Number   Contractual Life   Exercise   Number   Average
   Exercise Prices   Outstanding   in Years   Price   Exercisable   Exercise Price
$  7.00 — $10.00
    205,134       2.36     $ 8.39       205,134     $ 8.39  
$10.00 — $13.00
    167,000       3.63     $ 11.05       167,000     $ 11.05  
$17.00 — $19.00
    177,000       2.79     $ 17.92       177,000     $ 17.92  
Compensation Expense
     Effective January 1, 2006, the Company adopted SFAS No. 123R (Revised 2004), “Share-Based Payment”, which revises SFAS No. 123, “Accounting for Stock-Based Compensation", and supersedes APB Opinion No. 25, “Accounting for Stock Issued to Employees". SFAS No. 123R requires the Company to measure the cost of services received in exchange for equity instruments based on the grant-date fair value of the award, with the cost recognized over the requisite service or vesting period.
     As a result of its adoption of SFAS No. 123R, the Company recognizes compensation expense related to unvested options as of January 1, 2006. For the year ended December 31, 2006, the Company recognized

63


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
compensation expense of $150,800, approximately $93,000 after tax. For the three months ended March 31, 2007 and 2006, the Company recognized compensation expense of $17,700, approximately $11,000 after tax, and, $55,000, approximately $34,000 after tax, respectively. For the year ended March 31, 2008, the Company recognized compensation expense of $16,000, approximately $10,000 after tax. The amounts were calculated in prior periods using the Black-Scholes option pricing model. The Company does not expect to recognize any additional expense in fiscal 2009 relating to the aforementioned stock options.
     The Company issues shares of its restricted common stock to employees, pursuant to the Company’s restricted stock program, and the Company records compensation expense for the value of the shares issued over the requisite service period. In early 2005, the Company granted 24,197 shares valued at $259,633, or $10.73 per share, and throughout 2005, the Company granted 4,000 shares of restricted stock, with a value of $46,000. The Company recorded $841,650 in compensation expense for shares of restricted stock to be granted to employees in early 2006. During the three months ended March 31, 2007 and 2006, the Company recorded compensation expense of $102,766 and $37,477, respectively, related to its restricted stock program. In fiscal 2008, ended March 31, 2008, the Company recognized $664,296 in compensation expense related to its restricted stock program.
9. Commitments and Contingencies
Leases
     The Company leases its office facilities under a long-term leasing arrangement. The following is a schedule of future minimum lease payments at March 31, 2008 under the Company’s operating leases that have initial or remaining non-cancelable lease terms in excess of one year:
         
Year Ending      
March 31,   Leases  
2009
  $ 416,127  
2010
    523,257  
2011
    537,703  
2012
    517,374  
2013
    459,229  
Thereafter
    115,649  
 
     
Total Minimum Lease Payments
  $ 2,569,339  
 
     
     Rental expense charged to operations for the year ended March 31, 2008, three months ended March 31, 2007 and 2006, and the years ended December 31, 2006 and 2005 was $329,858, $80,765, $43,833, $136,189, and $147,188, respectively.
   Officer Indemnification
     Under its organizational documents, the Company’s officers, employees, and directors are indemnified against certain liability arising out of the performance of their duties to the Company. The Company also has an insurance policy for its directors and officers to insure them against liabilities arising from the performance of their duties required by their positions with the Company. The Company’s maximum exposure under these arrangements is unknown as this would involve future claims that may be made against the Company that have not yet occurred.
   Litigation
     The Company is involved in various product liability claims and other legal proceedings. The Company’s legal expense continues to have a significant impact on the results of operations as the Company defends itself against the various claims.
     For the fiscal year ended March 31, 2008, litigation expense decreased to approximately $2.5 million (net of $560,000 for insurance reimbursements), compared to $4.1 million for the twelve months ended March 31, 2007 (net of $1.6 million for insurance reimbursements). For the three-month transition period ended March 31, 2007, litigation expense was approximately $1.0 million, reduced by reimbursement of approximately $1.6 million from our insurance carriers for litigation expense incurred prior to 2006. For the fiscal year ended December 31, 2006,

64


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
litigation expense was approximately $6.0 million. In the fiscal year ended December 31, 2005, litigation expense was $6.2 million, reduced by reimbursement of approximately $2.0 million from our principal insurance carrier, resulting in net legal expense of approximately $4.2 million. In addition, net income and earnings per share for fiscal 2005 reflect the recording of approximately $8.5 million to settle the Arizona litigation and to create a reserve for any future payments related to the product liability litigation ($12 million settlement plus $1.3 million for the reserve, less $4.8 million expected to be covered by insurance). Various defendants in the lawsuits, including manufacturers and retailers, have sought indemnification or other recovery from us for damages related to the lawsuits.
     Among the principal matters pending to which the Company is a party are the following:
Product Liability
     Litigation relating to Zicam Cold Remedy nasal gel arises from claims that the product causes the permanent loss or diminishment of the sense of smell or smell and taste. The Company believes the studies that have been conducted and reviewed by independent medical and scientific experts and other evidence support our contention that these claims are unfounded.
     From late 2003 through March 2008, numerous lawsuits were filed against us alleging that our Zicam Cold Remedy product caused the permanent loss or diminishment of the sense of smell or smell and taste. On January 19, 2006, we entered into an agreement to settle claims made by approximately 90% of the plaintiffs (approximately 340 individuals) in all of the Zicam Cold Remedy product liability lawsuits pending against the Company at that time. This settlement related to the Arizona consolidated litigation, In Re Consolidated Zicam Product Liability Cases, Superior Court of Arizona (Maricopa County). The settlement documents acknowledge that Matrixx has denied and continues to deny any liability to the plaintiffs. Those plaintiffs who were eligible and elected to participate in the settlement program dismissed their claims with prejudice and provided written releases of their claims against the Company in return for their participation. Of the plaintiffs who did not participate in the settlement program, all have dismissed their claims as of July 31, 2007. Matrixx paid $11.9 million to fund awards to be made under the settlement program. In addition, Matrixx paid $100,000 to cover the administration of the settlement program by plaintiffs’ counsel. The Company recognized a charge of approximately $4.3 million (after tax) in the fourth quarter of 2005 to cover the portion of the settlement program costs not expected to be covered by insurance.
     Additionally, beginning on March 25, 2008, the case Bruno vs. Matrixx Initiatives, Inc. (filed July 7, 2006, in the Superior Court of the Sate of California, County of San Diego, Case No. 868821) was tried before a jury. On April 3, 2008 the jury delivered a unanimous verdict in favor of the Company. The Company cannot predict the timing of any additional trials with respect to the product liability lawsuits. Also, plaintiffs’ law firms may continue to solicit potential claimants through the Internet and other media; as a result, additional lawsuits may be filed against us.
Litigation Reserves
     We record accruals for such contingencies to the extent that we conclude their occurrence is probable and the related damages are estimable. If a range of liability is probable and estimable and no amount within the range appears to be a better estimate than any other amount within the range, we accrue the minimum of such probable range. Many claims involve highly complex issues relating to causation, label warnings, scientific evidence, actual damages and other matters. Often these issues are subject to substantial uncertainties and, therefore, the probability of loss and an estimation of damages are difficult to ascertain. Consequently, we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for these contingencies. Therefore, as of March 31, 2008, the Company maintained a reserve of approximately $1.1 million for any future payment of settlement or losses related to the cold remedy litigation. This reserve was based on certain assumptions some of which are described below, and was the amount that the Company believed that it could reasonably estimate would be spent to resolve the remaining cases that have been filed. Some of the significant factors that were considered in the amount of the reserve were as follows: the actual costs incurred by the Company up to that time in resolving several claims; the development of the Company’s legal defense strategy and structure in light of the recent settlement; and the number of cases that remain pending against the Company. There are events, such as the dismissal of any cases, the outcome of a trial, or rulings on pending evidentiary motions, that may have an impact on the Company’s conclusions as to the adequacy of the reserves for the pending product liability lawsuits. Litigation is

65


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
inherently unpredictable, and excessive verdicts do occur. Although we believe we have substantial defenses in these matters, we could in the future incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period. The Company will continue to review the adequacy of the associated reserves on a quarterly basis.
Securities Litigation Matters
     Two class action lawsuits were filed in April and May 2004 against the Company, our President and Chief Executive Officer, Carl J. Johnson, and our Executive Vice President and Chief Financial Officer, William J. Hemelt, alleging violations of federal securities laws. On January 18, 2005, the cases were consolidated and the court appointed James V. Sircusano as lead plaintiff. The amended complaint also includes our Vice President of Research and Development, Timothy L. Clarot, as a defendant and was filed March 4, 2005. The consolidated case is Sircusano, et al. vs. Matrixx Initiatives, Inc., et al., in the United States District Court, District of Arizona, Case No. CV04-0886 PHX DKD. Among other things, the lawsuit alleges that between October 2003 and February 2004, we made materially false and misleading statements regarding our Zicam Cold Remedy product, including failing to adequately disclose to the public the details of allegations that our products caused damage to the sense of smell and of certain of the product liability lawsuits described above. We believe the claims made in this lawsuit are without merit and are vigorously defending ourself in this matter. We filed a motion to dismiss this lawsuit and on March 8, 2006, the Company received an Order dated December 15, 2005 granting the motion to dismiss the case, without prejudice. In accordance with and subject to the provisions of the Company’s Certificate of Incorporation, Messrs. Johnson, Hemelt, and Clarot will be indemnified by the Company for their expenses incurred in defending these lawsuits and for any other losses which they may suffer as a result of these lawsuits. The Company has submitted this matter to its insurance carriers and may incur charges up to the deductible amount of $1 million. If any liability were to result from these lawsuits, which is not covered by insurance, we believe our financial results could be materially impacted.
Third-Party Manufacturers
     The Company’s third-party manufacturers are subject to reporting, facility inspection, and governmental review. In general, subsequent discovery of previously unrecognized problems or failure to comply with applicable regulatory requirements could result in restrictions on manufacturing or marketing of the Company’s products, product recalls or withdrawal, fines, seizure of product, as well as withdrawal or suspension of regulatory approvals. The manufacturer of several of our products is in the process of responding to observations made by the FDA during a routine facility inspection. The Company does not know how the conclusions of this review process might impact our products or business, but the review could result, with regard to those products manufactured at the facility, in any or all of the above consequences, including the possibility of a product recall.
10. Employee Benefit Plan
     Effective January 1, 2004, the Company adopted a Qualified 401(k) Retirement Account Plan, meeting the Safe Harbor Provisions of the IRS. The Company makes matching contributions relative to each employee’s Salary Reduction Contributions for the year of up to 4% of the employee’s compensation for the Plan year. For the year ended March 31, 2008, three months ended March 31, 2007 and 2006 and the years ended December 31, 2006 and 2005, the Company made matching contributions of $107,241, $33,128, $24,309, $85,813, and $96,103, respectively. Each employee is fully vested at all times in his or her contribution and the Company’s matching contributions.
11. Concentration of Credit Risk and Major Customers
     Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and limits its credit exposure with any one financial institution. The Company’s cash in its banks exceeds the federally insured limits. The Company provides credit in the normal course of business to many of the nation’s top drug stores and mass merchandisers. The Company’s accounts receivable are due from customers located throughout the United States. The Company performs periodic credit evaluations of its customers’ financial condition and generally requires no collateral. The Company maintains reserves for potential credit losses, and such losses have not exceeded management’s expectations.
     The Company’s sales are from products marketed under the Zicam, Nasal Comfort, and Xcid brand names, with a majority of its sales attributable to its Cold Remedy products, which subjects the Company to significant financial exposure. If future sales of these products decrease, and in particular sales of its Cold Remedy products, the Company’s operations could be materially adversely affected.
     The Company currently relies on third-party manufacturers to produce its products, and has identified alternative suppliers for some of its products. However, the Company has not made any purchases from these alternative suppliers.

66


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
     Sales to major customers, which comprised 10% or more of net sales, for the year ended March 31, 2008, three months ended March 31, 2007 and 2006, and the years ended December 31, 2006 and 2005 were as follows:
                                         
    Year ended   3 months ended   3 months ended   Year ended   Year ended
    March 31, 2008   March 31, 2007   March 31, 2006   December 31, 2006   December 31, 2005
Wal-Mart
    23.5 %     12.1 %     29.9 %     26.3 %     20.5 %
Walgreens
    13.3 %     *       *       12.6 %     14.6 %
CVS
    11.8 %     11.9 %     *       12.3 %     *  
 
*   Less than 10%
12. Fair Value of Financial Instruments
     Disclosures about Fair Value of Financial Instruments for the Company’s financial instruments are presented in the table below. These calculations are subjective in nature and involve uncertainties and significant matters of judgment and do not include income tax considerations. Therefore, the results cannot be determined with precision and cannot be substantiated by comparison to independent market values and may not be realized in actual sale or settlement of the instruments. There may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used could significantly affect the results. The following table presents a summary of the Company’s financial instruments as of March 31, 2008 and 2007:
                                 
    March 31, 2008   March 31, 2007
    Carrying   Estimated   Carrying   Estimated
    Amount   Fair Value   Amount   Fair Value
Fiancial Assets
                               
Cash and cash equivalents
  $ 27,932,672     $ 27,932,672     $ 16,944,189     $ 13,947,622  
Restricted cash
  $ 500,000     $ 500,000     $ 500,000     $ 500,000  
Financial Liabilities
                               
Long-term debt
                       
     The carrying amounts for cash and cash equivalents, receivables, accounts payable and accrued expenses approximate fair value because of the short maturities of these instruments.
13. Selected Quarterly Financial Data (Unaudited)
     Selected unaudited quarterly financial data for the year ended March 31, 2008, transition period ended March 31, 2007, and year ended December 31, 2006 are summarized below:
                                 
    Fiscal Year 2008 Quarters Ended:
    June 30, 2007   Sept. 30, 2007   Dec. 31, 2007   March 31, 2008
Net sales
  $ 8,573,428     $ 28,575,748     $ 30,801,567     $ 33,021,641  
Gross profit
    5,738,074       18,999,407       19,741,404       22,001,400  
Net income (loss) from operations
    (1,971,194 )     10,172,715       (1,176,811 )     8,786,894  
Net income (loss) per basic share
    (0.11 )     0.65       (0.07 )     0.60  
Net income (loss) per diluted share
    (0.11 )     0.63       (0.07 )     0.59  
Net income (loss)
    (1,062,906 )     6,409,228       (635,161 )     5,715,568  

67


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
         
    Transition Period
Ended:
    March 31, 2007
Net sales
  $ 19,045,754  
Gross profit
    11,998,099  
Net income (loss) from operations
    2,129,778  
Net income (loss) per basic share
    0.18  
Net income (loss) per diluted share
    0.17  
Net income (loss)
    1,709,231  
                                 
    Fiscal Year 2006 Quarters:  
    March 31, 2006     June 30, 2006     Sept. 30, 2006     Dec. 31, 2006  
Net sales
  $ 17,675,959     $ 8,206,133     $ 34,121,357     $ 36,227,332  
Gross profit
    11,810,748       5,801,426       22,967,447       23,205,681  
Net income (loss) from operations
    (8,606 )     (3,640,175 )     11,908,178       (1,105,172 )
Net income (loss) per basic share
    0.01       (0.19 )     0.74       (0.05 )
Net income (loss) per diluted share
    0.01       (0.19 )     0.72       (0.05 )
Net income (loss)
    96,760       (1,857,796 )     7,150,370       (462,705 )

68


Table of Contents

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES (cont.)
(a)2. Financial Statement Schedules
     Financial statement schedules have been omitted because either they are not required or are not applicable, or because the information has been included in the consolidated financial statements or notes thereto contained in this Annual Report on Form 10-K.
(a)3. Exhibits
     
Exhibit No.   Title
3.1
  Certificate of Incorporation and Amendments thereto of the Registrant (1)
 
   
3.2
  Bylaws of the Registrant (11)
 
   
4.1
  Rights Agreement dated as of July 22, 2002 by and between the Registrant and Corporate Stock Transfer, Inc. (2)
 
   
10.1
  Confidentiality and Non-Competition Agreement among the Registrant, Gel Tech, L.L.C. (now Zicam, LLC), Zensano, Inc., Zengen, Inc. and certain other individuals (4)
 
   
10.2
  *2001 Stock Incentive Plan (5)
 
   
10.2.1
  *Form of Matrixx Initiatives, Inc. 2001 Long-Term Incentive Plan Grant of Incentive Stock Option (7)
 
   
10.2.2
  *Form of Matrixx Initiatives, Inc. 2001 Long-Term Incentive Plan Restricted Stock Program Agreement (14)
 
   
10.2.3
  Form of Matrixx Initiatives, Inc. 2001 Long-Term Incentive Plan Restricted Stock Program Agreement (Directors) (13)
 
   
10.2.4
  First Amendment to the Matrixx Initiatives, Inc. 2001 Long-Term Incentive Plan Restricted Stock Program Agreements between the Registrant and Edward Walsh dated October 18, 2006 (13)
 
   
10.2.5
  First Amendment to the Matrixx Initiatives, Inc. 2001 Long-Term Incentive Plan Restricted Stock Program Agreements between the Registrant and Edward Faber dated October 18, 2006 (13)
 
   
10.3
  *Summary of Matrixx Initiatives, Inc. Director Restricted Stock Purchase Program (3)
 
   
10.4
  Manufacturing Agreement with BioZone Laboratories (6)
 
   
10.5
  Amended and Restated Credit Agreement dated September 27, 2005 among the Registrant, Zicam, LLC and Comerica Bank (9)
 
   
10.6.1
  Amendment Number One to Amended and Restated Credit Agreement and Waiver dated March 9, 2006 among the Registrant, Zicam LLC and Comerica Bank (15)
 
   
10.6.2
  Amendment Number Two to Amended and Restated Credit Agreement dated June 27, 2007 among the Registrant, Zicam LLC and Comerica Bank (15)
 
   
10.6.3
  Replacement Secured Promissory Note dated June 27, 2007 among the Registrant, Zicam, LLC and Comerica Bank (15)
 
   
10.6.4
  Amended and Restated Security Agreement dated September 27, 2005 among the Registrant, Zicam, LLC and Comerica Bank (9)
 
   
10.6.5
  Security Agreement and Collateral Assignment of Limited Liability Company Interests dated September 27, 2005 between Registrant and Comerica Bank (9)

69


Table of Contents

     
Exhibit No.   Title
10.6.6
  Amended and Restated Intellectual Property Security Agreement dated September 27, 2005 between Registrant and Comerica Bank (9)
 
   
10.6.7
  Amended and Restated Intellectual Property Security Agreement dated September 27, 2005 between Zicam, LLC and Comerica Bank (9)
 
   
10.6.8
  Security Agreement dated June 27, 2007 between Matrixx Oral Care, LLC and Comerica Bank (15)
 
   
10.7
  Form of Change of Control Agreement between Registrant and Registrant’s Executive Officers (15)
 
   
10.8
  Asset Purchase Agreement dated as of October 31, 2005 by and among Viridian Packaging Solutions, LLC, Beutlich, L.P., Frederic J. Beutlich and Zicam Swab Products, LLC (10)
 
   
10.9
  Settlement Agreement dated January 19, 2006 among the Registrant and the various plaintiffs in the consolidated products liability litigation (12)
 
   
10.10
  *Amended and Restated Employment Agreement dated October 18, 2006 among Registrant and Carl J. Johnson (13)
 
   
10.11
  *Insurance Agreement dated October 18, 2006 between the Registrant and William J. Hemelt (13)
 
   
21
  **Subsidiaries of the Registrant
 
   
23.1
  **Consent of Mayer Hoffman McCann P.C., independent registered public accounting firm
 
   
31.1
  **Certification of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
   
31.2
  **Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
   
32.1
  ***Certification of CEO pursuant to 18 U.S.C. Section 1350
 
   
32.2
  ***Certification of CFO pursuant to 18 U.S.C. Section 1350
 
*   Indicates management compensatory contract, plan or arrangement.
 
**   Filed with this Form 10-K.
 
***   Furnished with this Form 10-K.
 
(1)   Incorporated by reference to the Registrant’s Amendment No. 1 to Form 8-A, filed June 18, 2002, file number 000-27646.
 
(2)   Incorporated by reference to the Registrant’s registration statement on Form 8-A, filed July 23, 2002, file number 000-31404.
 
(3)   Incorporated by reference to the Registrant’s Report on Form 10-Q for the quarter ended June 30, 2006, file number 001-31404.
 
(4)   Incorporated by reference to the Registrant’s Report on Form 8-K filed December 14, 2001, file number 000-27646.
 
(5)   Incorporated by reference to the Registrant’s definitive proxy statement on Schedule 14A, filed April 8, 2005, file number 001-31404.
 
(6)   Incorporated by reference to the Registrant’s Report on Form 8-K filed October 28, 2004, file number 001-31404.

70


Table of Contents

(7)   Incorporated by reference to the Registrant’s Report on Form 8-K filed February 11, 2005 file number 001-31404.
 
(9)   Incorporated by reference to the Registrant’s Report on Form 8-K filed November 7, 2005, file number 001-31404.
 
(10)   Incorporated by reference to the Registrant’s Report on Form 8-K filed November 3, 2005, file number 001-31404.
 
(11)   Incorporated by reference to the Registrant’s Report on Form 8-K filed July 25, 2006, file number 001-31404.
 
(12)   Incorporated by reference to the Registrant’s Report on Form 8-K filed January 19, 2006, file number 001-31404.
 
(13)   Incorporated by reference to the Registrant’s Report on Form 10-Q for the period ended September 30, 2006, file number 001-31404.
 
(14)   Incorporated by reference to the Registrant’s Report on Form 8-K filed May 13, 2008, file number 001-31404.
 
(15)   Incorporated by reference to the Registrant’s Report on Form 10-Q for the period ended June 30, 2007, file number 001-31404.

71


Table of Contents

SIGNATURES
     Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, in Phoenix, Arizona, on June 12, 2008.
         
  MATRIXX INITIATIVES, INC.
 
 
  By:   /s/ Carl J. Johnson    
  Carl J. Johnson   
  President and Chief Executive Officer   
 
     Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dated indicated:
         
Signature   Title   Date
 
       
/s/ Edward E. Faber
  Chairman of the Board of Directors   June 12, 2008
 
       
Edward E. Faber
       
 
       
/s/ Carl J. Johnson
  President, Chief Executive Officer and Director   June 12, 2008
 
       
Carl J. Johnson
       
 
       
/s/ William C. Egan
  Director   June 12, 2008
 
       
William C. Egan
       
 
       
/s/ L. White Matthews, III
  Director   June 12, 2008
 
       
L. White Matthews, III
       
 
       
/s/ Michael A. Zeher
  Director   June 12, 2008
 
       
Michael A. Zeher
       
 
       
/s/ Samuel C. Cowley
Director, Executive Vice President Business   June 12, 2008
 
       
Samuel C. Cowley
  Development, General Counsel & Secretary    
 
       
/s/ John M. Clayton
  Director   June 12, 2008
 
       
John M. Clayton
       
 
       
/s/ Lori Bush
  Director   June 12, 2008
 
       
Lori Bush
       
 
       
/s/ William J. Hemelt
  Executive Vice President and Chief Financial Officer   June 12, 2008
 
       
William J. Hemelt
  (Principal Financial Officer & Principal Accounting Officer)    

72


Table of Contents

Exhibit Index
     
Exhibit No.   Title
 
   
21
  **Subsidiaries of the Registrant
 
   
23.1
  **Consent of Mayer Hoffman McCann P.C., independent registered public accounting firm
 
   
31.1
  **Certification of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
   
31.2
  **Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
   
32.1
  **Certification of CEO pursuant to 18 U.S.C. Section 1350.
 
   
32.2
  **Certification of CFO pursuant to 18 U.S.C. Section 1350.
 
**   Filed with this Form 10-K.
 
***   Furnished with this Form 10-K.

73

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki